User talk:Peter morrell/Selection of studies: Difference between revisions
Enric Naval (talk | contribs) I suggest you look at Help:Table and wikify the table code like I did with the header and first row. (I didn't include any font tags or cell size tags, so it's a bit uglier, u can beautify later) |
updated version, apparently. Copied from my talk page |
||
Line 1: | Line 1: | ||
Dear Tim,<br> |
Dear Tim,<br> |
||
Please put this on the Talk:Homeopathy Page and mention it is posted by me (or else the others may think I've bribed you); I'm not yet able to post there directly myself because the Page is semi-writeprotected.<br> |
Please put this on the Talk:Homeopathy Page and mention it is posted by me (or else the others may think I've bribed you); I'm not yet able to post there directly myself because the Page is semi-writeprotected.<br> |
||
Here are some of the studies/clinical trials:-</p> |
<p>Here are some of the studies/clinical trials:-</p> |
||
<p><b>STUDIES OF THE ACTIVITY OF HOMEOPATHIC MEDICINES</b></p> |
|||
<b> |
|||
<table border="1" cellpadding="0" style="mso-cellspacing: 1.5pt; mso-table-layout-alt: fixed" height="1087"> |
|||
<p align="left">STUDIES OF THE ACTIVITY OF HOMEOPATHIC MEDICINES</p> |
|||
< |
<tr style="height:6.75pt"> |
||
< |
<td width="162" style="width: 121.6pt; padding: .75pt" height="21"> |
||
<p class="MsoNormal" style="mso-line-height-alt:6.75pt"><span style="font-size: |
|||
<tr> |
|||
7.5pt">ORIGINAL/TRANSLATED TITLE</span></p> |
|||
</td> |
|||
<td width="128" height="9">AUTHOR(S)</td> |
|||
<td width="121" style="width: 91.05pt; padding: .75pt" height="21"> |
|||
<p class="MsoNormal" style="mso-line-height-alt:6.75pt">AUTHOR(S)</p> |
|||
</td> |
|||
<td width="203" height="9">STUDY</td> |
|||
<td width="111" style="width: 83.0pt; padding: .75pt" height="21"> |
|||
</tr> |
|||
<p class="MsoNormal" style="mso-line-height-alt:6.75pt">PUBLICATION</p> |
|||
<tr> |
|||
</td> |
|||
<td width="171" height="9"><font face="Optima-Bold" size="1"><b> |
|||
<td width="90" style="width: 67.45pt; padding: .75pt" height="21"> |
|||
<p align="left">Inhibition of lymphoblast</b></font></b> <font face="Optima-Bold" size="1"><b>transformation |
|||
<p class="MsoNormal" style="mso-line-height-alt:6.75pt">ACTIVITY</p> |
|||
test (LTT) in</b></font> <font face="Optima-Bold" size="1"><b>phytohaemagglutinin |
|||
</td> |
|||
(PHA) with</b></font> <font face="Optima-Bold" size="1"><b>Phytolacca |
|||
<td width="84" style="width: 62.9pt; padding: .75pt" height="21"> |
|||
americana in</b></font> <b><font face="Optima-Bold" size="1">homeopathic |
|||
<p class="MsoNormal" style="mso-line-height-alt:6.75pt">STUDY</p> |
|||
dilution</font></b></p> |
|||
</td> |
|||
</tr> |
|||
<td width="128" height="9"><font face="Optima" size="1"> |
|||
<tr style="height:6.75pt"> |
|||
<p align="left">Colas H.,</p> |
|||
<td width="162" style="width: 121.6pt; padding: .75pt" height="51"> |
|||
<p align="left">Aubin M.,</p> |
|||
<p><b><span style="font-size:7.5pt;font-family:Optima-Bold">Inhibition of |
|||
<p align="left">Picard P.,</p> |
|||
lymphoblast</span></b><span style="font-size:7.5pt;font-family:Optima-Bold"><br> |
|||
<b>transformation test (LTT) in</b><br> |
|||
</td> |
|||
<b>phytohaemagglutinin (PHA) with</b><br> |
|||
<td width="84" height="9"><i><font face="Optima-Oblique" size="1"> |
|||
<b>Phytolacca americana in</b><br> |
|||
<b>homeopathic dilution</b></span></p> |
|||
<p align="left">Fr.</font></i><font face="Optima" size="1">, </font><b><font face="Optima-Bold" size="1">1975</font></b><font face="Optima" size="1">, |
|||
</td> |
|||
<td width="121" style="width: 91.05pt; padding: .75pt" height="51"> |
|||
</td> |
|||
<p><span style="font-size:7.5pt;font-family:Optima">Colas H.,<br> |
|||
<td width="92" height="9"><b> |
|||
Aubin M.,<br> |
|||
<p align="left"><font face="Optima-Bold" size="1">Inhibitory</font></b></p> |
|||
< |
Picard P.,<br> |
||
Lebecq J.C.</span></p> |
|||
</td> |
|||
<p align="left"><font face="Optima" size="1">Lymphoblast</p> |
|||
<td width="111" style="width: 83.0pt; padding: .75pt" height="51"> |
|||
<p align="left">transformation</font></p> |
|||
<p><i><span style="font-size:7.5pt;font-family:Optima-Oblique">Ann. Homéopat.<o:p> |
|||
</td> |
|||
</ |
</o:p> |
||
< |
</span></i></p> |
||
<p><i><span style="font-size:7.5pt;font-family:Optima-Oblique">Fr.</span></i><span style="font-size:7.5pt;font-family:Optima">, |
|||
<td width="171" height="9"><font face="Optima-Bold" size="1"><b> |
|||
</span><b><span style="font-size:7.5pt;font-family:Optima-Bold">1975</span></b><span style="font-size:7.5pt;font-family:Optima">, |
|||
<p align="left">Inquiry into the limits of biological</b></font> <font face="Optima-Bold" size="1"><b>effects |
|||
6: 1-11.</span></p> |
|||
of chemical compounds in</b></font> <font face="Optima-Bold" size="1"><b>tissue |
|||
</td> |
|||
culture. I. Low dose effects of</b></font> <b><font face="Optima-Bold" size="1">mercure |
|||
<td width="90" style="width: 67.45pt; padding: .75pt" height="51"> |
|||
chloride</font></b></p> |
|||
<p style="mso-line-height-alt:6.75pt"><b><span style="font-size:7.5pt; |
|||
</td> |
|||
font-family:Optima-Bold">Inhibitory</span></b></p> |
|||
<td width="128" height="9"><font face="Optima" size="1"> |
|||
</td> |
|||
<p align="left">Mansvelt J.D.,</p> |
|||
<td width="84" style="width: 62.9pt; padding: .75pt" height="51"> |
|||
<p align="left">van Amons E.</font></p> |
|||
<p><span style="font-size:7.5pt;font-family:Optima">Lymphoblast<o:p> |
|||
</td> |
|||
< |
</o:p> |
||
</span></p> |
|||
<p align="left"><i><font face="Optima-Oblique" size="1">Z. |
|||
<p style="mso-line-height-alt:6.75pt"><span style="font-size:7.5pt; |
|||
Naturtorschung</font></i><font face="Optima" size="1">,</p> |
|||
font-family:Optima">transformation</span></p> |
|||
</font><b><font face="Optima-Bold" size="1"> |
|||
</td> |
|||
<p align="left">1975</font></b><font face="Optima" size="1">, 30:</p> |
|||
</tr> |
|||
<p align="left">643-649.</font></p> |
|||
<tr style="height:6.75pt"> |
|||
</td> |
|||
<td width="162" style="width: 121.6pt; padding: .75pt" height="38"> |
|||
<p><b><span style="font-size:7.5pt;font-family:Optima-Bold">Inquiry into |
|||
the limits of biological</span></b> <span style="font-size:7.5pt;font-family: |
|||
</td> |
|||
Optima-Bold"><b>effects of chemical compounds in</b></span> <b><span style="font-size:7.5pt;font-family:Optima-Bold">tissue |
|||
<td width="203" height="9"><font face="Optima" size="1"> |
|||
culture. I. Low dose effects of</span></b> <b><span style="font-size:7.5pt;font-family:Optima-Bold">mercuric |
|||
<p align="left">Lymphocyte</p> |
|||
chloride</span></b></p> |
|||
</td> |
|||
<td width="121" style="width: 91.05pt; padding: .75pt" height="38"><span style="font-size: 7.5pt; font-family: Optima">Mansvelt J.D.,<br> |
|||
</tr> |
|||
van Amons E.</span></td> |
|||
<tr> |
|||
<td width="111" style="width: 83.0pt; padding: .75pt" height="38"> |
|||
<p><i><span style="font-size:7.5pt;font-family:Optima-Oblique">Z. |
|||
<p align="left">The effects of Belladonna and</font></b> <font face="Optima-Bold" size="1"><b>Ferrum |
|||
Naturtorschung</span></i><span style="font-size:7.5pt;font-family:Optima">,<o:p> |
|||
</o:p> |
|||
of human</b></font> <b><font face="Optima-Bold" size="1">poly-morphonuclear |
|||
<br> |
|||
</span><b><span style="font-size:7.5pt;font-family:Optima-Bold">1975</span></b><span style="font-size:7.5pt;font-family:Optima">, |
|||
</td> |
|||
30:<br> |
|||
<td width="128" height="9"><font face="Optima" size="1"> |
|||
643-649.</span></p> |
|||
</td> |
|||
<p align="left">Aubin M.,</p> |
|||
<td width="90" style="width: 67.45pt; padding: .75pt" height="38"> |
|||
<p align="left">Royer J.F.</font></p> |
|||
<p style="mso-line-height-alt:6.75pt"><b><span style="font-size:7.5pt; |
|||
</td> |
|||
font-family:Optima-Bold">Inhibitory</span></b></p> |
|||
<td width="84" height="9"><i><font face="Optima-Oblique" size="1"> |
|||
</td> |
|||
<p align="left">Ann. Homéop. Fr.</font></i><font face="Optima" size="1">,</p> |
|||
<td width="84" style="width: 62.9pt; padding: .75pt" height="38"> |
|||
</font><b><font face="Optima-Bold" size="1"> |
|||
<p><span style="font-size:7.5pt;font-family:Optima">Lymphocyte<o:p> |
|||
</ |
</o:p> |
||
< |
</span></p> |
||
<p style="mso-line-height-alt:6.75pt"><span style="font-size:7.5pt; |
|||
font-family:Optima">growth</span></p> |
|||
</td> |
|||
</td> |
|||
<td width="203" height="9"><font face="Optima" size="1">Radical release</font></td> |
|||
</tr> |
|||
<tr style="height:6.75pt"> |
|||
<tr> |
|||
<td width="162" style="width: 121.6pt; padding: .75pt" height="47"> |
|||
<p><b><span style="font-size:7.5pt;font-family:Optima-Bold">The effects of |
|||
<p align="left">Effect of aconitum and veratrum</p> |
|||
Belladonna and</span></b> <b><span style="font-size:7.5pt;font-family:Optima-Bold">Ferrum |
|||
<p align="left">on the isolated perfused heart of</p> |
|||
phosphoricum on the</span></b> <b><span style="font-size:7.5pt;font-family: |
|||
Optima-Bold">chemoluminescence of human</span></b> <b><span style="font-size: |
|||
anguilla)</font></p> |
|||
7.5pt;font-family:Optima-Bold">poly-morphonuclear neutrophils</span></b></p> |
|||
</td> |
|||
</td> |
|||
<td width="128" height="8"><font face="Optima" size="1"> |
|||
<td width="121" style="width: 91.05pt; padding: .75pt" height="47"><span style="font-size: 7.5pt; font-family: Optima">Poitevin B.,<br> |
|||
<p align="left">Pennec J.P.,</p> |
|||
Aubin M.,<br> |
|||
</td> |
Royer J.F.</span></td> |
||
<td width="111" style="width: 83.0pt; padding: .75pt" height="47"> |
|||
<p><i><span style="font-size:7.5pt;font-family:Optima-Oblique">Ann. Homéop. |
|||
<p align="left">Comp. Biochem.</p> |
|||
Fr.</span></i><span style="font-size:7.5pt;font-family:Optima">,<o:p> |
|||
</o:p> |
|||
</ |
</span></p> |
||
< |
<p><b><span style="font-size:7.5pt;font-family:Optima-Bold">1983</span></b><span style="font-size:7.5pt;font-family:Optima">, |
||
3: 5-12.</span></p> |
|||
<td width="203" height="8"><font face="Optima" size="1">Aconitine toxicity</font></td> |
|||
</ |
</td> |
||
<td width="90" style="width: 67.45pt; padding: .75pt" height="47"> |
|||
<tr> |
|||
< |
<p style="mso-line-height-alt:6.75pt"><b><span style="font-size:7.5pt; |
||
font-family:Optima-Bold">Inhibitory</span></b></p> |
|||
<p align="left">Elements of homeopathic</p> |
|||
</td> |
|||
<p align="left">pharmacology</font></b></p> |
|||
<td width="84" style="width: 62.9pt; padding: .75pt" height="47"> |
|||
</td> |
|||
< |
<p class="MsoNormal" style="mso-line-height-alt:6.75pt"><span style="font-size: |
||
7.5pt;font-family:Optima">Radical release</span></p> |
|||
</td> |
|||
</tr> |
|||
<td width="84" height="8"><i><font face="Optima-Oblique" size="1"> |
|||
<tr style="height:6.0pt"> |
|||
<p align="left">Homéopathie</p> |
|||
<td width="162" style="width: 121.6pt; padding: .75pt" height="29"> |
|||
<p align="left">Franç.</font></i><font face="Optima" size="1">, </font><b><font face="Optima-Bold" size="1">1984</font></b><font face="Optima" size="1">, |
|||
<p><b><span style="font-size:7.5pt;font-family:Optima-Bold">Effect of |
|||
72:</p> |
|||
aconitum and veratrum on the isolated perfused heart of the common eel </span></b><span style="font-size:7.5pt;font-family:Optima">(Anguilla |
|||
<p align="left">231- 235</font></p> |
|||
</ |
anguilla)</span></p> |
||
</td> |
|||
<td width="92" height="8"><b><font face="Optima-Bold" size="1">Protective</font></b></td> |
|||
<td width="121" style="width: 91.05pt; padding: .75pt" height="29"><span style="font-size: 7.5pt; font-family: Optima">Pennec J.P.,<br> |
|||
</ |
Aubin M.</span></td> |
||
<td width="111" style="width: 83.0pt; padding: .75pt" height="29"> |
|||
<tr> |
|||
< |
<p><i><span style="font-size:7.5pt;font-family:Optima-Oblique">Comp. |
||
Biochem.<o:p> |
|||
<p align="left">The effect of homeopathic</p> |
|||
</o:p> |
|||
<p align="left">preparations on the phagocyte</p> |
|||
<br> |
|||
<p align="left">activity of granulocytes. In vitro</p> |
|||
Physiol.</span></i><span style="font-size:7.5pt;font-family:Optima">, </span><b><span style="font-size:7.5pt;font-family:Optima-Bold">1984</span></b><span style="font-size:7.5pt;font-family:Optima">,</span><span style="font-size: 7.5pt; font-family: Optima"><br> |
|||
<p align="left">tests and double-blind controlled</p> |
|||
776: 367-369.<br> |
|||
<p align="left">trials</font></b></p> |
|||
</ |
</span></p> |
||
</td> |
|||
<td width="128" height="8"><font face="Optima" size="1"> |
|||
<td width="90" style="width: 67.45pt; padding: .75pt" height="29"> |
|||
<p align="left">Wagner H.,</p> |
|||
<p class="MsoNormal" style="mso-line-height-alt:6.0pt"><b><span style="font-size:7.5pt;font-family:Optima-Bold">Protective</span></b></p> |
|||
<p align="left">Jurcic K.,</p> |
|||
</td> |
|||
<p align="left">Doenicke A.,</p> |
|||
<td width="84" style="width: 62.9pt; padding: .75pt" height="29"> |
|||
<p align="left">Rosenhuber E.,</p> |
|||
<p class="MsoNormal" style="mso-line-height-alt:6.0pt"><span style="font-size: |
|||
<p align="left">Behrens N.</font></p> |
|||
7.5pt;font-family:Optima">Aconitine toxicity</span></p> |
|||
</td> |
|||
</td> |
|||
<td width="84" height="8"><i><font face="Optima-Oblique" size="1"> |
|||
</tr> |
|||
<p align="left">Arzneim.</p> |
|||
<tr style="height:6.0pt"> |
|||
<p align="left">Forsch./Drug Res.</font></i><font face="Optima" size="1">,</p> |
|||
<td width="162" style="width: 121.6pt; padding: .75pt" height="7"> |
|||
</font><b><font face="Optima-Bold" size="1"> |
|||
<p><b><span style="font-size:7.5pt;font-family:Optima-Bold">Elements of |
|||
homeopathic pharmacology</span></b></p> |
|||
</td> |
|||
<td width="121" style="width: 91.05pt; padding: .75pt" height="7"> |
|||
< |
<p><span style="font-size:7.5pt;font-family:Optima">Aubin M.</span></p> |
||
</ |
</td> |
||
<td width="111" style="width: 83.0pt; padding: .75pt" height="7"> |
|||
<tr> |
|||
< |
<p><i><span style="font-size:7.5pt;font-family:Optima-Oblique">Homéopathie |
||
Franç.</span></i><span style="font-size:7.5pt;font-family:Optima">, </span><b><span style="font-size:7.5pt;font-family:Optima-Bold">1984</span></b><span style="font-size:7.5pt;font-family:Optima">, |
|||
<p align="left">Approach to quantitative analysis</p> |
|||
72:231- 235</span></p> |
|||
<p align="left">of the effect of Apis mellifica on</p> |
|||
</td> |
|||
<p align="left">the degranulation of human</p> |
|||
<td width="90" style="width: 67.45pt; padding: .75pt" height="7"> |
|||
<p align="left">basophils cultivated in vitro</font></b></p> |
|||
<p class="MsoNormal" style="mso-line-height-alt:6.0pt"><b><span style="font-size:7.5pt;font-family:Optima-Bold">Protective</span></b></p> |
|||
</td> |
|||
</td> |
|||
<td width="128" height="8"><font face="Optima" size="1"> |
|||
<td width="84" style="width: 62.9pt; padding: .75pt" height="7"> |
|||
<p align="left">Poitevin B.,</p> |
|||
<p class="MsoNormal" style="mso-line-height-alt:6.0pt"><span style="font-size: |
|||
<p align="left">Aubin M.,</p> |
|||
7.5pt;font-family:Optima">Aconitine toxicity</span></p> |
|||
</td> |
|||
</tr> |
|||
<td width="84" height="8"><i><font face="Optima-Oblique" size="1"> |
|||
<tr style="height:6.0pt"> |
|||
<p align="left">Innov. Tech. Biol.</p> |
|||
<td width="162" style="width: 121.6pt; padding: .75pt" height="25"> |
|||
<p align="left">Med.</font></i><font face="Optima" size="1">, </font><b><font face="Optima-Bold" size="1">1986</font></b><font face="Optima" size="1">, |
|||
<p><b><span style="font-size:7.5pt;font-family:Optima-Bold">The effect of |
|||
7:</p> |
|||
homeopathic preparations on the phagocyte activity of granulocytes. In |
|||
<p align="left">64-68.</font></p> |
|||
vitro tests and double-blind controlled trials</span></b></p> |
|||
</td> |
|||
</td> |
|||
<td width="92" height="8"><b><font face="Optima-Bold" size="1">Inhibitory</font></b></td> |
|||
<td width="121" style="width: 91.05pt; padding: .75pt" height="25"><span style="font-size: 7.5pt; font-family: Optima">Wagner H.,<br> |
|||
Jurcic K.,<br> |
|||
Doenicke A.,<br> |
|||
<p align="left">degranulation</font></p> |
|||
< |
Rosenhuber E.,<br> |
||
</ |
Behrens N.</span></td> |
||
<td width="111" style="width: 83.0pt; padding: .75pt" height="25"> |
|||
<tr> |
|||
< |
<p><i><span style="font-size:7.5pt;font-family:Optima-Oblique">Arzneim.<br> |
||
Forsch./Drug Res.,<br> |
|||
<p align="left">In vitro stimulation of human</font></b> <b><font face="Optima-Bold" size="1">granulocytes |
|||
</span></i><b><span style="font-size:7.5pt;font-family:Optima-Bold">1986</span></b><span style="font-size:7.5pt;font-family:Optima">, |
|||
</span><span style="font-size: 7.5pt; font-family: Optima">36:<br> |
|||
1424-1425.</span></p> |
|||
</td> |
|||
<td width="90" style="width: 67.45pt; padding: .75pt" height="25"> |
|||
<p class="MsoNormal" style="mso-line-height-alt:6.0pt"><b><span style="font-size:7.5pt;font-family:Optima-Bold">Stimulant</span></b></p> |
|||
<p align="left">Wagner H.,</p> |
|||
</td> |
|||
<p align="left">Kreher B.,</p> |
|||
<td width="84" style="width: 62.9pt; padding: .75pt" height="25"> |
|||
<p align="left">Jurcic K.</font></p> |
|||
<p class="MsoNormal" style="mso-line-height-alt:6.0pt"><span style="font-size: |
|||
</td> |
|||
7.5pt;font-family:Optima">Phagocytosis</span></p> |
|||
<td width="84" height="8"><font face="Optima-Oblique" size="1"><i> |
|||
</td> |
|||
<p align="left">Arzneim.</i></font> <b><font face="Optima-Oblique" size="1"><i>Forsch./Drug |
|||
</tr> |
|||
Res.</i></font><font face="Optima" size="1">,</font></b> <b><font face="Optima-Bold" size="1">1988</font><font face="Optima" size="1">, |
|||
<tr style="height:6.0pt"> |
|||
38:</font></b> <b><font face="Optima" size="1">273-275.</font></b></p> |
|||
<td width="162" style="width: 121.6pt; padding: .75pt" height="20"> |
|||
</td> |
|||
< |
<p><b><span style="font-size:7.5pt;font-family:Optima-Bold">Approach to |
||
quantitative analysis of the effect of Apis mellifica on the degranulation |
|||
<td width="203" height="8"><font face="Optima" size="1"> |
|||
of human basophils cultivated in vitro</span></b></p> |
|||
</td> |
|||
<p align="left">growth</font></p> |
|||
<td width="121" style="width: 91.05pt; padding: .75pt" height="20"><span style="font-size: 7.5pt; font-family: Optima">Poitevin B.,<br> |
|||
</td> |
|||
< |
Aubin M.,<br> |
||
Benveniste J.</span></td> |
|||
<tr> |
|||
<td width="111" style="width: 83.0pt; padding: .75pt" height="20"> |
|||
<p><i><span style="font-size:7.5pt;font-family:Optima-Oblique">Innov. |
|||
<p align="left">Human basophil degranulation</font></b> <b><font face="Optima-Bold" size="1">triggered |
|||
Tech. Biol.<br> |
|||
by very dilute antiserum</font></b> <b><font face="Optima-Bold" size="1">against |
|||
Med.</span></i><span style="font-size:7.5pt;font-family:Optima">, </span><b><span style="font-size:7.5pt;font-family:Optima-Bold">1986</span></b><span style="font-size:7.5pt;font-family:Optima">, |
|||
IgE</font></b></p> |
|||
</span><span style="font-size: 7.5pt; font-family: Optima">7:<br> |
|||
</td> |
|||
64-68.</span></p> |
|||
<td width="128" height="8"><font face="Optima" size="1"> |
|||
</td> |
|||
<p align="left">Davenas E.,</font> <font face="Optima" size="1"><b>Beauvais |
|||
<td width="90" style="width: 67.45pt; padding: .75pt" height="20"> |
|||
F.,</b></font> <font face="Optima" size="1"><b>Amara J.,</b></font> <font face="Optima" size="1"><b>Robinson |
|||
<p class="MsoNormal" style="mso-line-height-alt:6.0pt"><b><span style="font-size:7.5pt;font-family:Optima-Bold">Inhibitory</span></b></p> |
|||
M.,</b></font> <font face="Optima" size="1"><b>Miadonna A.,</b></font> <font face="Optima" size="1"><b>Tedeschi |
|||
</td> |
|||
A.,</b></font> <font face="Optima" size="1"><b>Pomeranz B.,</b></font> <font face="Optima" size="1"><b>Fortner |
|||
<td width="84" style="width: 62.9pt; padding: .75pt" height="20"> |
|||
P.,</b></font> <font face="Optima" size="1"><b>Belon P.,</b></font> <font face="Optima" size="1"><b>Sainte-Laudy |
|||
<p><span style="font-size:7.5pt;font-family:Optima">Basophil<o:p> |
|||
J.,</b></font> <font face="Optima" size="1"><b>Poitevin B.,</b></font> <b><font face="Optima" size="1">Benveniste |
|||
</o:p> |
|||
</ |
</span></p> |
||
< |
<p style="mso-line-height-alt:6.0pt"><span style="font-size:7.5pt;font-family: |
||
Optima">degranulation</span></p> |
|||
<p align="left">Nature</font></i><font face="Optima" size="1">, </font><b><font face="Optima-Bold" size="1">1988</font></b><font face="Optima" size="1">,</p> |
|||
</td> |
|||
<p align="left">333: 816-818.</font></p> |
|||
</tr> |
|||
<tr style="height:6.0pt"> |
|||
<td width="92" height="8"><b><font face="Optima-Bold" size="1">Stimulant</font></b></td> |
|||
<td width="162" style="width: 121.6pt; padding: .75pt" height="1"> |
|||
<p><b><span style="font-size:7.5pt;font-family:Optima-Bold">In vitro |
|||
<p align="left">Basophils</font></p> |
|||
stimulation of human</span></b> <b><span style="font-size:7.5pt;font-family: |
|||
</td> |
|||
Optima-Bold">granulocytes and lymphocytes by</span></b> <b><span style="font-size:7.5pt;font-family:Optima-Bold">pico- |
|||
</tr> |
|||
and femtogram quantities of</span></b> <b><span style="font-size:7.5pt;font-family:Optima-Bold">cytostatic |
|||
<tr> |
|||
agents</span></b></p> |
|||
<td width="171" height="8"><font face="Optima" size="1"> |
|||
</td> |
|||
<p align="left"></font><b><font face="Optima-Bold" size="1">In vitro |
|||
<td width="121" style="width: 91.05pt; padding: .75pt" height="1"><span style="font-size: 7.5pt; font-family: Optima">Wagner H.,<br> |
|||
immunological</p> |
|||
Kreher B.,<br> |
|||
<p align="left">degranulation of human basophils</p> |
|||
Jurcic K.</span></td> |
|||
<p align="left">is modulated by lung histamine</p> |
|||
<td width="111" style="width: 83.0pt; padding: .75pt" height="1"> |
|||
<p align="left">and Apis mellifica</font></b></p> |
|||
<p><i><span style="font-size:7.5pt;font-family:Optima-Oblique">Arzneim.</span></i> |
|||
</td> |
|||
<b><i><span style="font-size:7.5pt;font-family:Optima-Oblique">Forsch./Drug |
|||
<td width="128" height="8"><font face="Optima" size="1"> |
|||
Res.</span></i><span style="font-size:7.5pt;font-family:Optima">,</span></b> |
|||
<p align="left">Poitevin B.,</p> |
|||
<b><span style="font-size:7.5pt;font-family:Optima-Bold">1988</span><span style="font-size:7.5pt;font-family:Optima">, |
|||
<p align="left">Davenas E.,</p> |
|||
38:</span></b> <b><span style="font-size:7.5pt;font-family:Optima">273-275.</span></b></p> |
|||
</td> |
|||
<td width="90" style="width: 67.45pt; padding: .75pt" height="1"> |
|||
<p class="MsoNormal" style="mso-line-height-alt:6.0pt"><b><span style="font-size:7.5pt;font-family:Optima-Bold">Stimulant</span></b></p> |
|||
<p align="left">Brit. J. Clin.</p> |
|||
</td> |
|||
<p align="left">Pharmacol.</font></i><font face="Optima" size="1">, </font><b><font face="Optima-Bold" size="1">1988</font></b><font face="Optima" size="1">,</p> |
|||
<td width="84" style="width: 62.9pt; padding: .75pt" height="1"> |
|||
<p align="left">25: 439-444.</font></p> |
|||
<p><span style="font-size:7.5pt;font-family:Optima">Lymphocyte<o:p> |
|||
</td> |
|||
</o:p> |
|||
<td width="92" height="8"><b><font face="Optima-Bold" size="1">Inhibitory</font></b></td> |
|||
</span></p> |
|||
<td width="203" height="8"><font face="Optima" size="1"> |
|||
<p style="mso-line-height-alt:6.0pt"><span style="font-size:7.5pt;font-family: |
|||
<p align="left">Basophil</p> |
|||
Optima">growth</span></p> |
|||
</td> |
|||
</tr> |
|||
<tr style="height:6.0pt"> |
|||
<td width="162" style="width: 121.6pt; padding: .75pt" height="89"> |
|||
<p><b><span style="font-size:7.5pt;font-family:Optima-Bold">Human basophil |
|||
<p align="left">Cytotoxic agents as</p> |
|||
degranulation</span></b> <b><span style="font-size:7.5pt;font-family:Optima-Bold">triggered |
|||
<p align="left">immunomodulators</font></b></p> |
|||
by very dilute antiserum</span></b> <b><span style="font-size:7.5pt; |
|||
</td> |
|||
font-family:Optima-Bold">against IgE</span></b></p> |
|||
<td width="128" height="8"><font face="Optima" size="1"> |
|||
</td> |
|||
<p align="left">Wagner H.,</p> |
|||
<td width="121" style="width: 91.05pt; padding: .75pt" height="89"> |
|||
<p align="left">Kreher B.</font></p> |
|||
<p><span style="font-size:7.5pt;font-family:Optima">Davenas E.,</span> <span style="font-size:7.5pt;font-family:Optima">Beauvais |
|||
</td> |
|||
< |
F.,</span> <span style="font-size:7.5pt;font-family:Optima">Amara J.,</span> |
||
<span style="font-size:7.5pt;font-family:Optima">Robinson M.,</span> <span style="font-size:7.5pt;font-family:Optima">Miadonna |
|||
<p align="left">Proc. of the 3rd</p> |
|||
A.,</span> <span style="font-size:7.5pt;font-family:Optima">Tedeschi A.,</span> |
|||
<span style="font-size:7.5pt;font-family:Optima">Pomeranz B.,</span> <span style="font-size:7.5pt;font-family:Optima">Fortner |
|||
P.,</span> <span style="font-size:7.5pt;font-family:Optima">Belon P.,</span> |
|||
31-</p> |
|||
<span style="font-size:7.5pt;font-family:Optima">Sainte-Laudy J.,</span> <span style="font-size:7.5pt;font-family:Optima">Poitevin |
|||
<p align="left">46.</font></p> |
|||
B.,</span> <span style="font-size:7.5pt;font-family:Optima">Benveniste J.</span></p> |
|||
</td> |
|||
</td> |
|||
<td width="92" height="8"><b><font face="Optima-Bold" size="1">Stimulant</font></b></td> |
|||
<td width="111" style="width: 83.0pt; padding: .75pt" height="89"> |
|||
<p><i><span style="font-size:7.5pt;font-family:Optima-Oblique">Nature</span></i><span style="font-size:7.5pt;font-family:Optima">, |
|||
<p align="left">Lymphocyte</p> |
|||
</span><b><span style="font-size:7.5pt;font-family:Optima-Bold">1988</span></b><span style="font-size:7.5pt;font-family:Optima">,<o:p> |
|||
<p align="left">growth</font></p> |
|||
</ |
</o:p> |
||
</ |
</span></p> |
||
<p><span style="font-size:7.5pt;font-family:Optima">333: 816-818.</span></p> |
|||
<tr> |
|||
</td> |
|||
<td width="171" height="8"><b><font face="Optima-Bold" size="1"> |
|||
<td width="90" style="width: 67.45pt; padding: .75pt" height="89"> |
|||
<p align="left">Contributions of fundamental</p> |
|||
<p class="MsoNormal" style="mso-line-height-alt:6.0pt"><b><span style="font-size:7.5pt;font-family:Optima-Bold">Stimulant</span></b></p> |
|||
<p align="left">research in homeopathy</font></b></p> |
|||
</td> |
|||
<td width="84" style="width: 62.9pt; padding: .75pt" height="89"> |
|||
<p style="mso-line-height-alt:6.0pt"><span style="font-size:7.5pt;font-family: |
|||
<p align="left">Boiron J.,</p> |
|||
Optima">Basophils</span></p> |
|||
</td> |
|||
</tr> |
|||
<td width="84" height="8"><i><font face="Optima-Oblique" size="1"> |
|||
<tr style="height:6.0pt"> |
|||
<p align="left">Berl. J. Res. Hom.</font></i><font face="Optima" size="1">,</p> |
|||
<td width="162" style="width: 121.6pt; padding: .75pt" height="30"> |
|||
</font><b><font face="Optima-Bold" size="1"> |
|||
<p><b><span style="font-size:7.5pt;font-family:Optima-Bold">In vitro |
|||
immunological degranulation of human basophils is modulated by lung |
|||
</td> |
|||
histamine and Apis mellifica</span></b></p> |
|||
<td width="92" height="8"><b><font face="Optima-Bold" size="1">Inhibitory</font></b></td> |
|||
</td> |
|||
<td width="203" height="8"><font face="Optima" size="1"> |
|||
<td width="121" style="width: 91.05pt; padding: .75pt" height="30"><span style="font-size: 7.5pt; font-family: Optima">Poitevin B.,<br> |
|||
<p align="left">Basophil</p> |
|||
Davenas E.,<br> |
|||
<p align="left">degranulation</font></p> |
|||
</td> |
Benveniste J.</span></td> |
||
<td width="111" style="width: 83.0pt; padding: .75pt" height="30"> |
|||
</tr> |
|||
<p><i><span style="font-size:7.5pt;font-family:Optima-Oblique">Brit. J. Clin.<br> |
|||
<tr> |
|||
Pharmacol.</span></i><span style="font-size:7.5pt;font-family:Optima">, </span><b><span style="font-size:7.5pt;font-family:Optima-Bold">1988</span></b><span style="font-size:7.5pt;font-family:Optima">,<br> |
|||
<td width="171" height="8"><b><font face="Optima-Bold" size="1"> |
|||
25: 439-444.</span></p> |
|||
<p align="left">Synergism of action between</p> |
|||
</td> |
|||
<p align="left">indoleacetic acid (IAA) and highly</p> |
|||
<td width="90" style="width: 67.45pt; padding: .75pt" height="30"> |
|||
<p align="left">diluted solutions of CaCO3 on the</p> |
|||
<p class="MsoNormal" style="mso-line-height-alt:6.0pt"><b><span style="font-size:7.5pt;font-family:Optima-Bold">Inhibitory</span></b></p> |
|||
<p align="left">growth of oat coleoptiles</font></b></p> |
|||
</td> |
|||
<td width="84" style="width: 62.9pt; padding: .75pt" height="30"><span style="font-size: 7.5pt; font-family: Optima">Basophil<br> |
|||
degranulation</span></td> |
|||
<td width="84" height="8"><i><font face="Optima-Oblique" size="1"> |
|||
</tr> |
|||
<p align="left">Berl. J. Res. Hom.</font></i><font face="Optima" size="1">,</p> |
|||
<tr style="height:6.0pt"> |
|||
</font><b><font face="Optima-Bold" size="1"> |
|||
<td width="162" style="width: 121.6pt; padding: .75pt" height="1"> |
|||
<p align="left">1991</font></b><font face="Optima" size="1">, 1 (4/5):</p> |
|||
<p><b><span style="font-size:7.5pt;font-family:Optima-Bold">Cytotoxic |
|||
agents as immunomodulators</span></b></p> |
|||
</td> |
|||
</td> |
|||
<td width="92" height="8"><b><font face="Optima-Bold" size="1">Stimulant</font></b></td> |
|||
<td width="121" style="width: 91.05pt; padding: .75pt" height="1"><span style="font-size: 7.5pt; font-family: Optima">Wagner H.,<br> |
|||
Kreher B.</span></td> |
|||
<td width="111" style="width: 83.0pt; padding: .75pt" height="1"> |
|||
<p align="left">cells</font></p> |
|||
<p><i><span style="font-size:7.5pt;font-family:Optima-Oblique">Proc. of |
|||
</td> |
|||
< |
the 3rd<br> |
||
GIRI meetin</span></i><span style="font-size:7.5pt;font-family:Optima">g,<br> |
|||
<tr> |
|||
Paris, </span><b><span style="font-size:7.5pt;font-family:Optima-Bold">1989</span></b><span style="font-size:7.5pt;font-family:Optima">, |
|||
</span><span style="font-size: 7.5pt; font-family: Optima">31-<br> |
|||
<p align="left">Study of the action of</p> |
|||
46.</span></p> |
|||
</td> |
|||
<p align="left">mercury chloride on the mitotic</p> |
|||
<td width="90" style="width: 67.45pt; padding: .75pt" height="1"> |
|||
<p align="left">index in animal cell cultures.</font></b></p> |
|||
<p class="MsoNormal" style="mso-line-height-alt:6.0pt"><b><span style="font-size:7.5pt;font-family:Optima-Bold">Stimulant</span></b></p> |
|||
</td> |
|||
</td> |
|||
<td width="128" height="8"><font face="Optima" size="1"> |
|||
<td width="84" style="width: 62.9pt; padding: .75pt" height="1"> |
|||
<p align="left">Boiron J.,</p> |
|||
<p><span style="font-size:7.5pt;font-family:Optima">Lymphocyte<o:p> |
|||
</o:p> |
|||
</span></p> |
|||
<p style="mso-line-height-alt:6.0pt"><span style="font-size:7.5pt;font-family: |
|||
</td> |
|||
Optima">growth</span></p> |
|||
<td width="84" height="8"><i><font face="Optima-Oblique" size="1"> |
|||
</td> |
|||
<p align="left">Ann. Homéop.</p> |
|||
</tr> |
|||
<p align="left">Fr</font></i><font face="Optima" size="1">., </font><b><font face="Optima-Bold" size="1">1991</font></b><font face="Optima" size="1">, |
|||
<tr style="height:6.0pt"> |
|||
23:</p> |
|||
<td width="162" style="width: 121.6pt; padding: .75pt" height="15"> |
|||
<p align="left">43-49.</font></p> |
|||
<p><b><span style="font-size:7.5pt;font-family:Optima-Bold">Contributions |
|||
</td> |
|||
of fundamental research in homeopathy</span></b></p> |
|||
</td> |
|||
<td width="203" height="8"><font face="Optima" size="1">Hg toxicity</font></td> |
|||
<td width="121" style="width: 91.05pt; padding: .75pt" height="15"><span style="font-size: 7.5pt; font-family: Optima">Boiron J.,<br> |
|||
</tr> |
|||
< |
Belon P.</span></td> |
||
<td width="111" style="width: 83.0pt; padding: .75pt" height="15"> |
|||
<p><i><span style="font-size:7.5pt;font-family:Optima-Oblique">Berl. J. |
|||
<p align="left">Dual effects of formylpeptides on</p> |
|||
Res. Hom.,<br> |
|||
<p align="left">the adhesion of endotoxin-primed</p> |
|||
</span></i><b><span style="font-size:7.5pt;font-family:Optima-Bold">1990</span></b><span style="font-size:7.5pt;font-family:Optima">, |
|||
<p align="left">human neutrophils</font></b></p> |
|||
</ |
1: 34-35.</span></p> |
||
</td> |
|||
<td width="128" height="8"><font face="Optima" size="1"> |
|||
<td width="90" style="width: 67.45pt; padding: .75pt" height="15"> |
|||
<p align="left">Bellavite P.,</p> |
|||
<p class="MsoNormal" style="mso-line-height-alt:6.0pt"><b><span style="font-size:7.5pt;font-family:Optima-Bold">Inhibitory</span></b></p> |
|||
<p align="left">Chirumbolo S.,</p> |
|||
</td> |
|||
<p align="left">Lippi G.,</p> |
|||
<td width="84" style="width: 62.9pt; padding: .75pt" height="15"><span style="font-size: 7.5pt; font-family: Optima">Basophil<br> |
|||
<p align="left">Andrioli G.,</p> |
|||
degranulation</span></td> |
|||
</tr> |
|||
<p align="left">Ferro I.</font></p> |
|||
<tr style="height:6.0pt"> |
|||
</td> |
|||
<td width="162" style="width: 121.6pt; padding: .75pt" height="13"> |
|||
<p><b><span style="font-size:7.5pt;font-family:Optima-Bold">Synergism of |
|||
<p align="left">Cell. Biochem.</p> |
|||
action between indoleacetic acid (IAA) and highlydiluted solutions of |
|||
<p align="left">Funct.</font></i><font face="Optima" size="1">, </font><b><font face="Optima-Bold" size="1">1993</font></b><font face="Optima" size="1">, |
|||
CaCO3 on the growth of oat coleoptiles</span></b></p> |
|||
</td> |
|||
<p align="left">231-239.</font></p> |
|||
<td width="121" style="width: 91.05pt; padding: .75pt" height="13"> |
|||
</td> |
|||
<p class="MsoNormal"><span style="font-size:7.5pt;font-family:Optima">Bornoroni |
|||
<td width="92" height="8"><b><font face="Optima-Bold" size="1">Inhibitory</font></b></td> |
|||
C.</span></p> |
|||
<td width="203" height="8"><font face="Optima" size="1"> |
|||
</td> |
|||
<p align="left">Cell adhesion</p> |
|||
<td width="111" style="width: 83.0pt; padding: .75pt" height="13"> |
|||
<p align="left">(bact. pept.</p> |
|||
<p><i><span style="font-size:7.5pt;font-family:Optima-Oblique">Berl. J. |
|||
<p align="left">10-8-10-9)</font></p> |
|||
Res. Hom.,</span></i><b><span style="font-size:7.5pt;font-family:Optima-Bold"><br> |
|||
</td> |
|||
1991</span></b><span style="font-size:7.5pt;font-family:Optima">, 1 (4/5): |
|||
</tr> |
|||
< |
275-278.</span></p> |
||
</td> |
|||
<td width="171" height="8"><b><font face="Optima-Bold" size="1"> |
|||
<td width="90" style="width: 67.45pt; padding: .75pt" height="13"> |
|||
<p align="left">Effects of homeopathic</p> |
|||
<p class="MsoNormal" style="mso-line-height-alt:6.0pt"><b><span style="font-size:7.5pt;font-family:Optima-Bold">Stimulant</span></b></p> |
|||
<p align="left">preparations of organic acids and</p> |
|||
</td> |
|||
<p align="left">of minerals on the oxidative</p> |
|||
<td width="84" style="width: 62.9pt; padding: .75pt" height="13"> |
|||
<p align="left">metabolism of human neutrophils</font></b></p> |
|||
<p><span style="font-size:7.5pt;font-family:Optima">Growth of plant </span><span style="font-size:7.5pt;font-family: |
|||
</td> |
|||
Optima">cells</span></p> |
|||
<td width="128" height="8"><font face="Optima" size="1"> |
|||
</td> |
|||
<p align="left">Chirumbolo S.,</p> |
|||
</tr> |
|||
<p align="left">Signorini A.,</p> |
|||
<tr style="height:6.0pt"> |
|||
<p align="left">Bianchi I.,</p> |
|||
<td width="162" style="width: 121.6pt; padding: .75pt" height="23"> |
|||
<p align="left">Lippi G.,</p> |
|||
<p><b><span style="font-size:7.5pt;font-family:Optima-Bold">Study of the |
|||
<p align="left">Bellavite P.</font></p> |
|||
action of Hahnemannian dilutions of mercury chloride on the mitotic index |
|||
</td> |
|||
in animal cell cultures.</span></b></p> |
|||
<td width="84" height="8"><i><font face="Optima-Oblique" size="1"> |
|||
</td> |
|||
<p align="left">Br. Hom. J.</font></i><font face="Optima" size="1">, </font><b><font face="Optima-Bold" size="1">1993</font></b><font face="Optima" size="1">,</p> |
|||
<td width="121" style="width: 91.05pt; padding: .75pt" height="23"><span style="font-size: 7.5pt; font-family: Optima">Boiron J.,<br> |
|||
<p align="left">82: 227-244.</font></p> |
|||
< |
Abecassis J.,<br> |
||
Cotte J.,<br> |
|||
<td width="92" height="8"><b><font face="Optima-Bold" size="1">Inhibitory</font></b></td> |
|||
Bernard A.M.</span></td> |
|||
<td width="203" height="8"><font face="Optima" size="1"> |
|||
<td width="111" style="width: 83.0pt; padding: .75pt" height="23"> |
|||
<p align="left">Leucocyte</p> |
|||
<p><i><span style="font-size:7.5pt;font-family:Optima-Oblique">Ann. Homé</span></i><i><span style="font-size:7.5pt;font-family:Optima-Oblique">op.Fr</span></i><span style="font-size:7.5pt;font-family:Optima">., |
|||
<p align="left">activation</p> |
|||
</span><b><span style="font-size:7.5pt;font-family:Optima-Bold">1991</span></b><span style="font-size:7.5pt;font-family:Optima">, |
|||
<p align="left">(metabolism)</font></p> |
|||
< |
23:<o:p> |
||
</ |
</o:p> |
||
< |
</span></p> |
||
<p><span style="font-size:7.5pt;font-family:Optima">43-49.</span></p> |
|||
<td width="171" height="8"><b><font face="Optima-Bold" size="1"> |
|||
</td> |
|||
<p align="left">Platelets/endothelial cells</p> |
|||
<td width="90" style="width: 67.45pt; padding: .75pt" height="23"> |
|||
<p align="left">interactions in presence of</p> |
|||
<p class="MsoNormal" style="mso-line-height-alt:6.0pt"><b><span style="font-size:7.5pt;font-family:Optima-Bold">Protective</span></b></p> |
|||
<p align="left">acetylsalicylic acid at ultra low</p> |
|||
</td> |
|||
<p align="left">dose</font></b></p> |
|||
<td width="84" style="width: 62.9pt; padding: .75pt" height="23"> |
|||
</td> |
|||
< |
<p class="MsoNormal" style="mso-line-height-alt:6.0pt"><span style="font-size: |
||
7.5pt;font-family:Optima">Hg toxicity</span></p> |
|||
<p align="left">Doutremepuich</p> |
|||
</td> |
|||
</tr> |
|||
<p align="left">Lalanne M.C.,</p> |
|||
<tr style="height:6.0pt"> |
|||
<p align="left">Ramboer I.,</p> |
|||
<td width="162" style="width: 121.6pt; padding: .75pt" height="48"> |
|||
<p align="left">Sertillanges</p> |
|||
<p><b><span style="font-size:7.5pt;font-family:Optima-Bold">Dual effects |
|||
<p align="left">M.N.,</p> |
|||
of formylpeptides on the adhesion of endotoxin-primed human neutrophils</span></b></p> |
|||
<p align="left">De Seze O.</font></p> |
|||
</td> |
|||
<td width="121" style="width: 91.05pt; padding: .75pt" height="48"><span style="font-size: 7.5pt; font-family: Optima">Bellavite P.,<br> |
|||
Chirumbolo S.,<br> |
|||
<p align="left">Omeomed 92 (C.</p> |
|||
Lippi G.,<br> |
|||
<p align="left">Bornoroni, ed.)</font></i><font face="Optima" size="1">,</p> |
|||
Andrioli G.,<br> |
|||
</font><b><font face="Optima-Bold" size="1"> |
|||
Bonazzi L.,<br> |
|||
<p align="left">1993</font></b><font face="Optima" size="1">, Editrice</p> |
|||
Ferro I.</span></td> |
|||
<td width="111" style="width: 83.0pt; padding: .75pt" height="48"> |
|||
<p align="left">Bologna:</p> |
|||
<p><i><span style="font-size:7.5pt;font-family:Optima-Oblique">Cell. Biochem.<br> |
|||
Funct.</span></i><span style="font-size:7.5pt;font-family:Optima">, </span><b><span style="font-size:7.5pt;font-family:Optima-Bold">1993</span></b><span style="font-size:7.5pt;font-family:Optima">, |
|||
</td> |
|||
11: 231-239.</span></p> |
|||
<td width="92" height="8"><b><font face="Optima-Bold" size="1">Inhibitory</font></b></td> |
|||
</td> |
|||
<td width="203" height="8"><font face="Optima" size="1"> |
|||
<td width="90" style="width: 67.45pt; padding: .75pt" height="48"> |
|||
<p align="left">Prostacyclin</p> |
|||
<p class="MsoNormal" style="mso-line-height-alt:6.0pt"><b><span style="font-size:7.5pt;font-family:Optima-Bold">Inhibitory</span></b></p> |
|||
<p align="left">release</font></p> |
|||
</td> |
|||
<td width="84" style="width: 62.9pt; padding: .75pt" height="48"> |
|||
</tr> |
|||
<p class="MsoNormal"><span style="font-size:7.5pt;mso-bidi-font-size:12.0pt;font-family:"Times New Roman"; |
|||
<tr> |
|||
mso-fareast-font-family:"Times New Roman";mso-ansi-language:EN-GB;mso-fareast-language: |
|||
<td width="171" height="8"><b><font face="Optima-Bold" size="1"> |
|||
EN-US;mso-bidi-language:AR-SA">Cell adhesion<br> |
|||
<p align="left">Effect of high dilutions of epidermal</p> |
|||
(bact. pept.<br> |
|||
<p align="left">growth factor (EGF) on </font><i><font face="Optima-BoldOblique" size="1">in |
|||
10<sup>-8</sup>-10<sup>-9</sup>)</span></td> |
|||
vitro</p> |
|||
</tr> |
|||
</font></i><font face="Optima-Bold" size="1"> |
|||
<tr style="height:6.0pt"> |
|||
<p align="left">proliferation of keratinocyte and</p> |
|||
<td width="162" style="width: 121.6pt; padding: .75pt" height="23"> |
|||
<p align="left">fibroblast cell lines</font></b></p> |
|||
<p><b><span style="font-size:7.5pt;font-family:Optima-Bold">Effects of |
|||
</td> |
|||
homeopathic preparations of organic acids and of minerals on the oxidative |
|||
<td width="128" height="8"><font face="Optima" size="1"> |
|||
metabolism of human neutrophils</span></b></p> |
|||
</td> |
|||
<p align="left">Moubry K.,</p> |
|||
<td width="121" style="width: 91.05pt; padding: .75pt" height="23"><span style="font-size: 7.5pt; font-family: Optima">Chirumbolo S.,<br> |
|||
<p align="left">Vallot N.,</p> |
|||
Signorini A.,<br> |
|||
<p align="left">Bastide M.</font></p> |
|||
< |
Bianchi I.,<br> |
||
Lippi G.,<br> |
|||
<td width="84" height="8"><i><font face="Optima-Oblique" size="1"> |
|||
Bellavite P.</span></td> |
|||
<p align="left">Br. Hom. J.</font></i><font face="Optima" size="1">, </font><b><font face="Optima-Bold" size="1">1993</font></b><font face="Optima" size="1">,</p> |
|||
<td width="111" style="width: 83.0pt; padding: .75pt" height="23"> |
|||
<p align="left">82: 124-125.</font></p> |
|||
<p><i><span style="font-size:7.5pt;font-family:Optima-Oblique">Br. Hom. J.</span></i><span style="font-size:7.5pt;font-family:Optima">, |
|||
</td> |
|||
< |
</span><b><span style="font-size:7.5pt;font-family:Optima-Bold">1993</span></b><span style="font-size:7.5pt;font-family:Optima">,<o:p> |
||
</o:p> |
|||
<td width="203" height="8"><font face="Optima" size="1"> |
|||
</span></p> |
|||
<p><span style="font-size:7.5pt;font-family:Optima">82: 227-244.</span></p> |
|||
</td> |
|||
<td width="90" style="width: 67.45pt; padding: .75pt" height="23"> |
|||
</tr> |
|||
<p class="MsoNormal" style="mso-line-height-alt:6.0pt"><b><span style="font-size:7.5pt;font-family:Optima-Bold">Inhibitory</span></b></p> |
|||
<tr> |
|||
</td> |
|||
<td width="171" height="8"><b><font face="Optima-Bold" size="1"> |
|||
<td width="84" style="width: 62.9pt; padding: .75pt" height="23"><span style="font-size: 7.5pt; font-family: Optima">Leucocyte<br> |
|||
<p align="left">Effects of different homeopathic</p> |
|||
activation<br> |
|||
<p align="left">potencies of Lachesis on</p> |
|||
(metabolism)</span></td> |
|||
<p align="left">lymphocyte cultures obtained</p> |
|||
</tr> |
|||
<p align="left">from rabbit blood</font></b></p> |
|||
<tr style="height:6.0pt"> |
|||
</td> |
|||
<td width="162" style="width: 121.6pt; padding: .75pt" height="51"> |
|||
<p><b><span style="font-size:7.5pt;font-family:Optima-Bold">Platelets/endothelial |
|||
<p align="left">Enbergs H.,</p> |
|||
cells interactions in presence of acetylsalicylic acid at ultra low dose</span></b></p> |
|||
<p align="left">Arndt G.</font></p> |
|||
</td> |
|||
<td width="121" style="width: 91.05pt; padding: .75pt" height="51"><span style="font-size: 7.5pt; font-family: Optima">Doutremepuich<br> |
|||
C.,<br> |
|||
<p align="left">Biol. Tier., </font><b><font face="Optima-BoldOblique" size="1">1993</font></b><font face="Optima-Oblique" size="1">,</p> |
|||
Lalanne M.C.,<br> |
|||
<p align="left">4.</font></i></p> |
|||
< |
Ramboer I.,<br> |
||
Sertillanges<br> |
|||
<td width="92" height="8"><b><font face="Optima-Bold" size="1">Stimulant</font></b></td> |
|||
M.N.,<br> |
|||
<td width="203" height="8"><font face="Optima" size="1"> |
|||
< |
De Seze O.</span></td> |
||
<td width="111" style="width: 83.0pt; padding: .75pt" height="51"> |
|||
<p align="left">immunostimulating</p> |
|||
<p><i><span style="font-size:7.5pt;font-family:Optima-Oblique">Omeomed 92 |
|||
<p align="left">activity (bact. pept</p> |
|||
(C.<br> |
|||
<p align="left">10-5-10-6)</font></p> |
|||
Bornoroni, ed.),</span></i><b><span style="font-size:7.5pt;font-family:Optima-Bold"><br> |
|||
</td> |
|||
1993</span></b><span style="font-size:7.5pt;font-family:Optima">, </span><span style="font-size: 7.5pt; font-family: Optima">Editrice<br> |
|||
</tr> |
|||
< |
Compositori,<br> |
||
Bologna:<br> |
|||
<td width="171" height="8"><b><font face="Optima-Bold" size="1"> |
|||
109-115.</span></p> |
|||
</td> |
|||
<p align="left">potencies of housedust mite on</p> |
|||
<td width="90" style="width: 67.45pt; padding: .75pt" height="51"> |
|||
<p align="left">the migration of house-dust sensitive</p> |
|||
<p class="MsoNormal" style="mso-line-height-alt:6.0pt"><b><span style="font-size:7.5pt;font-family:Optima-Bold">Inhibitory</span></b></p> |
|||
<p align="left">human leukocytes</font></b></p> |
|||
</td> |
|||
<td width="84" style="width: 62.9pt; padding: .75pt" height="51"> |
|||
<p><span style="font-size:7.5pt;font-family:Optima">Prostacyclin<o:p> |
|||
</o:p> |
|||
</ |
</span></p> |
||
< |
<p style="mso-line-height-alt:6.0pt"><span style="font-size:7.5pt;font-family: |
||
Optima">release</span></p> |
|||
<p align="left">Complement.</p> |
|||
</td> |
|||
<p align="left">Ther. Med.</font></i><font face="Optima" size="1">, </font><b><font face="Optima-Bold" size="1">1996</font></b><font face="Optima" size="1">,</p> |
|||
</tr> |
|||
<p align="left">4: 169-171.</font></p> |
|||
<tr style="height:6.0pt"> |
|||
</td> |
|||
<td width="162" style="width: 121.6pt; padding: .75pt" height="29"> |
|||
<p><b><span style="font-size:7.5pt;font-family:Optima-Bold">Effect of high |
|||
<td width="203" height="8"><font face="Optima" size="1"> |
|||
dilutions of epidermal growth factor (EGF) on </span><i><span style="font-size:7.5pt;font-family:Optima-BoldOblique">in |
|||
<p align="left">Leucocyte</p> |
|||
vitro </span></i><span style="font-size:7.5pt;font-family:Optima-Bold">proliferation |
|||
<p align="left">chemotaxis</font></p> |
|||
of keratinocyte and fibroblast cell lines</span></b></p> |
|||
</td> |
|||
</ |
</td> |
||
<td width="121" style="width: 91.05pt; padding: .75pt" height="29"><span style="font-size: 7.5pt; font-family: Optima">Fougeray S.,<br> |
|||
<tr> |
|||
Moubry K.,<br> |
|||
<td width="171" height="8"><b><font face="Optima-Bold" size="1"> |
|||
Vallot N.,<br> |
|||
<p align="left">The effects of Nux vomica</p> |
|||
Bastide M.</span></td> |
|||
<p align="left">Homaccord and Atropinum comp.</p> |
|||
<td width="111" style="width: 83.0pt; padding: .75pt" height="29"> |
|||
<p align="left">on intestinal activity in vitro</font></b></p> |
|||
<p><i><span style="font-size:7.5pt;font-family:Optima-Oblique">Br. Hom. J.</span></i><span style="font-size:7.5pt;font-family:Optima">, |
|||
</td> |
|||
</span><b><span style="font-size:7.5pt;font-family:Optima-Bold">1993</span></b><span style="font-size:7.5pt;font-family:Optima">,<o:p> |
|||
<td width="128" height="8"><font face="Optima" size="1"> |
|||
</o:p> |
|||
</span></p> |
|||
<p><span style="font-size:7.5pt;font-family:Optima">82: 124-125.</span></p> |
|||
</td> |
|||
</td> |
|||
<td width="84" height="8"><i><font face="Optima-Oblique" size="1"> |
|||
<td width="90" style="width: 67.45pt; padding: .75pt" height="29"> |
|||
<p align="left">Biol. Tier.</font></i><font face="Optima" size="1">, </font><b><font face="Optima-Bold" size="1">1996</font></b><font face="Optima" size="1">/1,</p> |
|||
<p class="MsoNormal" style="mso-line-height-alt:6.0pt"><b><span style="font-size:7.5pt;font-family:Optima-Bold">Inhibitory</span></b></p> |
|||
<p align="left">43-47.</font></p> |
|||
</td> |
|||
<td width="84" style="width: 62.9pt; padding: .75pt" height="29"> |
|||
< |
<p><span style="font-size:7.5pt;font-family:Optima">Growth of<o:p> |
||
</o:p> |
|||
</span></p> |
|||
<p style="mso-line-height-alt:6.0pt"><span style="font-size:7.5pt;font-family: |
|||
</td> |
|||
Optima">keratinocytes</span></p> |
|||
</tr> |
|||
< |
</td> |
||
</tr> |
|||
<td width="171" height="8"><b><font face="Optima-Bold" size="1"> |
|||
<tr style="height:6.0pt"> |
|||
<p align="left">Application of flow cytometry to</p> |
|||
<td width="162" style="width: 121.6pt; padding: .75pt" height="26"> |
|||
<p align="left">the analysis of the</p> |
|||
<p><b><span style="font-size:7.5pt;font-family:Optima-Bold">Effects of |
|||
<p align="left">immunosuppressive effect of</p> |
|||
different homeopathic potencies of Lachesis on lymphocyte cultures |
|||
<p align="left">histamine dilutions on human</p> |
|||
obtained from rabbit blood</span></b></p> |
|||
<p align="left">basophil action: effect of</p> |
|||
</td> |
|||
<p align="left">cimetidine</font></b></p> |
|||
<td width="121" style="width: 91.05pt; padding: .75pt" height="26"><span style="font-size: 7.5pt; font-family: Optima">Enbergs H.,<br> |
|||
</td> |
|||
Arndt G.</span></td> |
|||
<td width="128" height="8"><font face="Optima" size="1"> |
|||
<td width="111" style="width: 83.0pt; padding: .75pt" height="26"> |
|||
<p align="left">Sainte-Laudy J.,</p> |
|||
<p><i><span style="font-size:7.5pt;font-family:Optima-Oblique">Biol. |
|||
<p align="left">Belon P.</font></p> |
|||
Tier., </span></i><b><i><span style="font-size:7.5pt;font-family:Optima-BoldOblique">1993</span></i></b><i><span style="font-size:7.5pt;font-family:Optima-Oblique">, |
|||
</td> |
|||
4.</span></i></p> |
|||
<td width="84" height="8"><i><font face="Optima-Oblique" size="1"> |
|||
</td> |
|||
<p align="left">Inflamm. Res</font></i><font face="Optima" size="1">.,</p> |
|||
<td width="90" style="width: 67.45pt; padding: .75pt" height="26"> |
|||
</font><b><font face="Optima-Bold" size="1"> |
|||
<p class="MsoNormal" style="mso-line-height-alt:6.0pt"><b><span style="font-size:7.5pt;font-family:Optima-Bold">Stimulant</span></b></p> |
|||
<p align="left">1997</font></b><font face="Optima" size="1">, 46:</p> |
|||
</td> |
|||
<p align="left">S27-S28.</font></p> |
|||
<td width="84" style="width: 62.9pt; padding: .75pt" height="26"><span style="font-size: 7.5pt; font-family: Optima">Mitotic and<br> |
|||
</td> |
|||
immunostimulating<br> |
|||
<td width="92" height="8"><b><font face="Optima-Bold" size="1">Inhibitory</font></b></td> |
|||
activity (bact. pept<br> |
|||
<td width="203" height="8"><font face="Optima" size="1"> |
|||
</span><span style="font-size:7.5pt;mso-bidi-font-size:12.0pt;font-family:"Times New Roman"; |
|||
<p align="left">Basophil</p> |
|||
mso-fareast-font-family:"Times New Roman";mso-ansi-language:EN-GB;mso-fareast-language: |
|||
<p align="left">degranulation</font></p> |
|||
EN-US;mso-bidi-language:AR-SA">10<sup>-5</sup>-10<sup>-6</sup></span><span style="font-size: 7.5pt; font-family: Optima">)</span></td> |
|||
</td> |
|||
</tr> |
|||
<tr style="height:6.0pt"> |
|||
<td width="162" style="width: 121.6pt; padding: .75pt" height="40"> |
|||
<p><b><span style="font-size:7.5pt;font-family:Optima-Bold">The effect of |
|||
<p align="left">Effects of Podophillum pellatum</p> |
|||
homeopathic potencies of housedust mite on the migration of house-dust |
|||
<p align="left">compounds in various</p> |
|||
sensitive human leukocytes</span></b></p> |
|||
<p align="left">preparations and dilutions on</p> |
|||
</td> |
|||
<p align="left">human neutrophil functions in</p> |
|||
<td width="121" style="width: 91.05pt; padding: .75pt" height="40"><span style="font-size: 7.5pt; font-family: Optima">Gibson S.L.,<br> |
|||
<p align="left">vitro</font></b></p> |
|||
</td> |
Gibson R.G.</span></td> |
||
<td width="111" style="width: 83.0pt; padding: .75pt" height="40"> |
|||
<p><i><span style="font-size:7.5pt;font-family:Optima-Oblique">Complement.<br> |
|||
<p align="left">Chirumbolo S.,</p> |
|||
Ther. Med.</span></i><span style="font-size:7.5pt;font-family:Optima">, </span><b><span style="font-size:7.5pt;font-family:Optima-Bold">1996</span></b><span style="font-size:7.5pt;font-family:Optima">,<br> |
|||
<p align="left">Conforti A.,</p> |
|||
4: 169-171.</span></p> |
|||
</td> |
|||
<p align="left">Metelmann H.</p> |
|||
<td width="90" style="width: 67.45pt; padding: .75pt" height="40"> |
|||
<p align="left">et Al.</font></p> |
|||
<p class="MsoNormal" style="mso-line-height-alt:6.0pt"><b><span style="font-size:7.5pt;font-family:Optima-Bold">Stimulant</span></b></p> |
|||
</td> |
|||
</td> |
|||
<td width="84" height="8"><i><font face="Optima-Oblique" size="1"> |
|||
<td width="84" style="width: 62.9pt; padding: .75pt" height="40"><span style="font-size: 7.5pt; font-family: Optima">Leucocyte<br> |
|||
<p align="left">Br. Hom. J</font></i><font face="Optima" size="1">., </font><b><font face="Optima-Bold" size="1">1997</font></b><font face="Optima" size="1">;</p> |
|||
chemotaxis</span></td> |
|||
</tr> |
|||
<tr style="height:6.0pt"> |
|||
<td width="92" height="8"><b><font face="Optima-Bold" size="1">Inhibitory</font></b></td> |
|||
<td width="162" style="width: 121.6pt; padding: .75pt" height="20"> |
|||
<p><b><span style="font-size:7.5pt;font-family:Optima-Bold">The effects of |
|||
<p align="left">Release of</p> |
|||
Nux vomica Homaccord and Atropinum comp. on intestinal activity in vitro</span></b></p> |
|||
<p align="left">superoxides</font></p> |
|||
</td> |
|||
<td width="121" style="width: 91.05pt; padding: .75pt" height="20"><span style="font-size: 7.5pt; font-family: Optima">Kanui T.I.,<br> |
|||
</tr> |
|||
< |
Enbergs H.</span></td> |
||
<td width="111" style="width: 83.0pt; padding: .75pt" height="20"> |
|||
<p><i><span style="font-size:7.5pt;font-family:Optima-Oblique">Biol. Tier.</span></i><span style="font-size:7.5pt;font-family:Optima">, |
|||
</span><b><span style="font-size:7.5pt;font-family:Optima-Bold">1996</span></b><span style="font-size:7.5pt;font-family:Optima">/1, |
|||
43-47.</span></p> |
|||
</td> |
|||
<p align="left">efficiency of potentized and nonpotentized</p> |
|||
<td width="90" style="width: 67.45pt; padding: .75pt" height="20"> |
|||
<p align="left">substances</font></b></p> |
|||
<p class="MsoNormal" style="mso-line-height-alt:6.0pt"><b><span style="font-size:7.5pt;font-family:Optima-Bold">Stimulant</span></b></p> |
|||
</td> |
|||
</td> |
|||
<td width="128" height="8"><font face="Optima" size="1"> |
|||
<td width="84" style="width: 62.9pt; padding: .75pt" height="20"><span style="font-size: 7.5pt; font-family: Optima">Contraction of<br> |
|||
<p align="left">Harisch G.,</p> |
|||
intestinal muscles</span></td> |
|||
</tr> |
|||
<tr style="height:6.0pt"> |
|||
<td width="84" height="8"><i><font face="Optima-Oblique" size="1"> |
|||
<td width="162" style="width: 121.6pt; padding: .75pt" height="7"> |
|||
<p align="left">BT, </font></i><b><font face="Optima-Bold" size="1">1997</font></b><font face="Optima" size="1">, |
|||
<p><b><span style="font-size:7.5pt;font-family:Optima-Bold">Application of |
|||
2;</p> |
|||
flow cytometry to the analysis of the immunosuppressive effect of |
|||
<p align="left">40-46.</font></p> |
|||
histamine dilutions on human basophil action: effect ofcimetidine</span></b></p> |
|||
</td> |
|||
</td> |
|||
<td width="92" height="8"><font face="Optima" size="1"> |
|||
<td width="121" style="width: 91.05pt; padding: .75pt" height="7"><span style="font-size: 7.5pt; font-family: Optima">Sainte-Laudy J.,<br> |
|||
<p align="left">Difference between</p> |
|||
Belon P.</span></td> |
|||
<td width="111" style="width: 83.0pt; padding: .75pt" height="7"> |
|||
<p align="left">non-potentised</p> |
|||
<p><i><span style="font-size:7.5pt;font-family:Optima-Oblique">Inflamm. Res.,<br> |
|||
<p align="left">substances</font></p> |
|||
</span></i><b><span style="font-size:7.5pt;font-family:Optima-Bold">1997</span></b><span style="font-size:7.5pt;font-family:Optima">, |
|||
</td> |
|||
< |
4</span><span style="font-size: 7.5pt; font-family: Optima">6:<br> |
||
S27-S28.</span></p> |
|||
<p align="left">In vivo </font></i><font face="Optima" size="1">and </font><i><font face="Optima-Oblique" size="1">in</p> |
|||
</td> |
|||
<p align="left">vitro </font></i><font face="Optima" size="1">study; |
|||
<td width="90" style="width: 67.45pt; padding: .75pt" height="7"> |
|||
basic</p> |
|||
<p class="MsoNormal" style="mso-line-height-alt:6.0pt"><b><span style="font-size:7.5pt;font-family:Optima-Bold">Inhibitory</span></b></p> |
|||
<p align="left">research</font></p> |
|||
</td> |
|||
<td width="84" style="width: 62.9pt; padding: .75pt" height="7"><span style="font-size: 7.5pt; font-family: Optima">Basophil<br> |
|||
</tr> |
|||
degranulation</span></td> |
|||
<tr> |
|||
</tr> |
|||
<td width="171" height="8"><b><font face="Optima-Bold" size="1"> |
|||
<tr style="height:6.0pt"> |
|||
<p align="left">Experiments with the effects of</p> |
|||
<td width="162" style="width: 121.6pt; padding: .75pt" height="31"> |
|||
<p align="left">Ubichinon-Injeel and strong</p> |
|||
<p><b><span style="font-size:7.5pt;font-family:Optima-Bold">Effects of |
|||
<p align="left">Ubichinon-Injeel on an acellular</p> |
|||
Podophillum pellatum compounds in various preparations and dilutions on |
|||
<p align="left">system</font></b></p> |
|||
human neutrophil functions in vitro</span></b></p> |
|||
</td> |
|||
</td> |
|||
<td width="128" height="8"><font face="Optima" size="1"> |
|||
<td width="121" style="width: 91.05pt; padding: .75pt" height="31"><span style="font-size: 7.5pt; font-family: Optima">Chirumbolo S.,<br> |
|||
<p align="left">Harisch G.,</p> |
|||
Conforti A.,<br> |
|||
<p align="left">Dittmann J.</font></p> |
|||
< |
Lussignoli S.,<br> |
||
Metelmann H.<br> |
|||
<td width="84" height="8"><i><font face="Optima-Oblique" size="1"> |
|||
et Al.</span></td> |
|||
<p align="left">BM, </font></i><b><font face="Optima-Bold" size="1">1997</font></b><font face="Optima" size="1">, |
|||
<td width="111" style="width: 83.0pt; padding: .75pt" height="31"> |
|||
3;</p> |
|||
<p><i><span style="font-size:7.5pt;font-family:Optima-Oblique">Br. Hom. J</span></i><span style="font-size:7.5pt;font-family:Optima">., |
|||
<p align="left">99-104.</font></p> |
|||
</span><b><span style="font-size:7.5pt;font-family:Optima-Bold">1997</span></b><span style="font-size:7.5pt;font-family:Optima">;<o:p> |
|||
</td> |
|||
</o:p> |
|||
<td width="92" height="8"><font face="Optima" size="1"> |
|||
</span></p> |
|||
<p><span style="font-size:7.5pt;font-family:Optima">86-16.</span></p> |
|||
</td> |
|||
<p align="left">various potencies and</p> |
|||
<td width="90" style="width: 67.45pt; padding: .75pt" height="31"> |
|||
<p align="left">individual potencies</font></p> |
|||
<p class="MsoNormal" style="mso-line-height-alt:6.0pt"><b><span style="font-size:7.5pt;font-family:Optima-Bold">Inhibitory</span></b></p> |
|||
</td> |
|||
</td> |
|||
<td width="203" height="8"><i><font face="Optima-Oblique" size="1"> |
|||
<td width="84" style="width: 62.9pt; padding: .75pt" height="31"> |
|||
<p align="left">In vitro </font></i><font face="Optima" size="1">study;</p> |
|||
<p><span style="font-size:7.5pt;font-family:Optima">Release of<o:p> |
|||
<p align="left">basic research</font></p> |
|||
</ |
</o:p> |
||
</ |
</span></p> |
||
<p style="mso-line-height-alt:6.0pt"><span style="font-size:7.5pt;font-family: |
|||
<tr> |
|||
Optima">superoxides</span></p> |
|||
<td width="171" height="8"><b><font face="Optima-Bold" size="1"> |
|||
</td> |
|||
<p align="left">Efficacy of the homeopathic drugs</p> |
|||
</tr> |
|||
<p align="left">Suis and Arnica comp.-Heel® on</p> |
|||
<tr style="height:6.0pt"> |
|||
<p align="left">lymphocyte and phagocyte</p> |
|||
<td width="162" style="width: 121.6pt; padding: .75pt" height="1"> |
|||
<p align="left">activity</font></b></p> |
|||
<p><b><i><span style="font-size:7.5pt;font-family:Optima-BoldOblique">In |
|||
</td> |
|||
vivo </span></i><span style="font-size:7.5pt;font-family:Optima-Bold">and </span><i><span style="font-size:7.5pt;font-family:Optima-BoldOblique">in |
|||
<td width="128" height="8"><font face="Optima" size="1">Enbergs H.</font></td> |
|||
< |
vitro </span></i><span style="font-size:7.5pt;font-family:Optima-Bold">studies |
||
on the efficiency of potentized and nonpotentized substances</span></b></p> |
|||
<p align="left">BM, </font></i><b><font face="Optima-Bold" size="1">1998</font></b><font face="Optima" size="1">, |
|||
</td> |
|||
<td width="121" style="width: 91.05pt; padding: .75pt" height="1"><span style="font-size: 7.5pt; font-family: Optima">Harisch G.,<br> |
|||
<p align="left">3-11.</font></p> |
|||
</td> |
Dittmann J.</span></td> |
||
<td width="111" style="width: 83.0pt; padding: .75pt" height="1"> |
|||
<p><i><span style="font-size:7.5pt;font-family:Optima-Oblique">BT, </span></i><b><span style="font-size:7.5pt;font-family:Optima-Bold">1997</span></b><span style="font-size:7.5pt;font-family:Optima">, |
|||
<p align="left">Effect of</p> |
|||
2;<o:p> |
|||
<p align="left">organotherapeutics</p> |
|||
</o:p> |
|||
</span></p> |
|||
<p><span style="font-size:7.5pt;font-family:Optima">40-46.</span></p> |
|||
</td> |
|||
<td width="90" style="width: 67.45pt; padding: .75pt" height="1"> |
|||
<p><span style="font-size:7.5pt;font-family:Optima">Difference between |
|||
potentised and non-potentised substances</span></p> |
|||
</td> |
|||
<td width="84" style="width: 62.9pt; padding: .75pt" height="1"> |
|||
</tr> |
|||
<p style="mso-line-height-alt:6.0pt"><i><span style="font-size:7.5pt; |
|||
<tr> |
|||
font-family:Optima-Oblique">In vivo </span></i><span style="font-size:7.5pt; |
|||
<td width="171" height="8"><b><font face="Optima-Bold" size="1"> |
|||
font-family:Optima">and </span><i><span style="font-size:7.5pt;font-family: |
|||
<p align="left">Influence of dilutions and</p> |
|||
Optima-Oblique">in vitro </span></i><span style="font-size:7.5pt;font-family: |
|||
<p align="left">potencies of cAMP on different</p> |
|||
Optima">study; basic research</span></p> |
|||
</td> |
|||
</tr> |
|||
<td width="128" height="8"><font face="Optima" size="1"> |
|||
<tr style="height:6.0pt"> |
|||
<p align="left">Harisch G.,</p> |
|||
<td width="162" style="width: 121.6pt; padding: .75pt" height="21"> |
|||
<p align="left">Dittmann J.</font></p> |
|||
<p><b><span style="font-size:7.5pt;font-family:Optima-Bold">Experiments |
|||
</td> |
|||
with the effects of Ubichinon-Injeel and strong Ubichinon-Injeel on an |
|||
<td width="84" height="8"><i><font face="Optima-Oblique" size="1"> |
|||
acellular system</span></b></p> |
|||
<p align="left">BM, </font></i><b><font face="Optima-Bold" size="1">1998</font></b><font face="Optima" size="1">, |
|||
</td> |
|||
<td width="121" style="width: 91.05pt; padding: .75pt" height="21"><span style="font-size: 7.5pt; font-family: Optima">Harisch G.,<br> |
|||
<p align="left">55-62.</font></p> |
|||
</td> |
Dittmann J.</span></td> |
||
<td width="111" style="width: 83.0pt; padding: .75pt" height="21"> |
|||
<p><i><span style="font-size:7.5pt;font-family:Optima-Oblique">BM, </span></i><b><span style="font-size:7.5pt;font-family:Optima-Bold">1997</span></b><span style="font-size:7.5pt;font-family:Optima">, |
|||
<p align="left">Effects of dilutions</p> |
|||
3;<o:p> |
|||
</o:p> |
|||
</span></p> |
|||
<p><span style="font-size:7.5pt;font-family:Optima">99-104.</span></p> |
|||
</td> |
|||
</td> |
|||
<td width="203" height="8"><i><font face="Optima-Oblique" size="1"> |
|||
<td width="90" style="width: 67.45pt; padding: .75pt" height="21"> |
|||
<p align="left">In vitro </font></i><font face="Optima" size="1">study;</p> |
|||
<p><span style="font-size:7.5pt;font-family:Optima">Different effects of |
|||
<p align="left">basic research</font></p> |
|||
associations of various potencies and individual potencies</span></p> |
|||
</td> |
|||
</ |
</td> |
||
<td width="84" style="width: 62.9pt; padding: .75pt" height="21"> |
|||
<tr> |
|||
<p><i><span style="font-size:7.5pt;font-family:Optima-Oblique">In vitro </span></i><span style="font-size:7.5pt;font-family:Optima">study;<o:p> |
|||
<td width="171" height="8"><b><font face="Optima-Bold" size="1"> |
|||
</o:p> |
|||
<p align="left">Studies of the principles of</p> |
|||
</span></p> |
|||
<p style="mso-line-height-alt:6.0pt"><span style="font-size:7.5pt;font-family: |
|||
<p align="left">from </font><i><font face="Optima-BoldOblique" size="1">in |
|||
Optima">basic research</span></p> |
|||
vivo </font></i><font face="Optima-Bold" size="1">to </font><i><font face="Optima-BoldOblique" size="1">in |
|||
</td> |
|||
</tr> |
|||
</font></i><font face="Optima-Bold" size="1"> |
|||
<tr style="height:6.0pt"> |
|||
<p align="left">experimental research</font></b></p> |
|||
<td width="162" style="width: 121.6pt; padding: .75pt" height="15"> |
|||
</td> |
|||
<p><b><span style="font-size:7.5pt;font-family:Optima-Bold">Efficacy of |
|||
<td width="128" height="8"><font face="Optima" size="1"> |
|||
the homeopathic drugs Suis and Arnica comp.-Heel® on lymphocyte and |
|||
<p align="left">Harisch G.,</p> |
|||
phagocyte activity</span></b></p> |
|||
</td> |
|||
<td width="121" style="width: 91.05pt; padding: .75pt" height="15"> |
|||
<p class="MsoNormal"><span style="font-size:7.5pt;font-family:Optima">Enbergs |
|||
H.</span></p> |
|||
</td> |
|||
<p align="left">98-103.</font></p> |
|||
<td width="111" style="width: 83.0pt; padding: .75pt" height="15"> |
|||
</td> |
|||
<p><i><span style="font-size:7.5pt;font-family:Optima-Oblique">BM, </span></i><b><span style="font-size:7.5pt;font-family:Optima-Bold">1998</span></b><span style="font-size:7.5pt;font-family:Optima">, |
|||
<td width="92" height="8"><font face="Optima" size="1"> |
|||
1;<o:p> |
|||
</o:p> |
|||
</span></p> |
|||
<p><span style="font-size:7.5pt;font-family:Optima">3-11.</span></p> |
|||
</td> |
|||
<p align="left">but have different</p> |
|||
<td width="90" style="width: 67.45pt; padding: .75pt" height="15"> |
|||
<p align="left">actions</font></p> |
|||
<p style="mso-line-height-alt:6.0pt"><span style="font-size:7.5pt;font-family: |
|||
</td> |
|||
Optima">Effect of organotherapeutics and Arnica comp. -Heel® on immune system |
|||
<td width="203" height="8"> |
|||
cells</span></p> |
|||
<p align="left"><font face="Optima-Oblique" size="1">B</font><font face="Optima" size="1">asic |
|||
</td> |
|||
<td width="84" style="width: 62.9pt; padding: .75pt" height="15"> |
|||
</td> |
|||
<p><i><span style="font-size:7.5pt;font-family:Optima-Oblique">In vitro </span></i><span style="font-size:7.5pt;font-family:Optima">study;<o:p> |
|||
</tr> |
|||
< |
</o:p> |
||
</span></p> |
|||
<td width="171" height="8"><font face="Optima-Bold" size="1"><b> |
|||
<p style="mso-line-height-alt:6.0pt"><span style="font-size:7.5pt;font-family: |
|||
<p align="left">Determination of the activity of</b></font> <b><font face="Optima-Bold" size="1">acid |
|||
Optima">basic research</span></p> |
|||
phosphatase with cAMP at</font></b> <b><font face="Optima-Bold" size="1">various |
|||
</td> |
|||
</tr> |
|||
<tr style="height:6.0pt"> |
|||
<td width="162" style="width: 121.6pt; padding: .75pt" height="14"> |
|||
<p align="left">Harisch G.,</p> |
|||
<p><b><span style="font-size:7.5pt;font-family:Optima-Bold">Influence of |
|||
<p align="left">Dittmann J.</font></p> |
|||
dilutions and potencies of cAMP on different enzymatic systems</span></b></p> |
|||
</td> |
|||
</td> |
|||
<td width="84" height="8"><i><font face="Optima-Oblique" size="1">BM, </font></i><b><font face="Optima-Bold" size="1">1999</font></b><font face="Optima" size="1">, |
|||
<td width="121" style="width: 91.05pt; padding: .75pt" height="14"><span style="font-size: 7.5pt; font-family: Optima">Harisch G.,<br> |
|||
1; 4-8.</font></td> |
|||
Dittmann J.</span></td> |
|||
<td width="92" height="8"><font face="Optima" size="1"> |
|||
<td width="111" style="width: 83.0pt; padding: .75pt" height="14"> |
|||
<p align="left">Different effects on</font> <font face="Optima" size="1">enzymatic |
|||
<p><i><span style="font-size:7.5pt;font-family:Optima-Oblique">BM, </span></i><b><span style="font-size:7.5pt;font-family:Optima-Bold">1998</span></b><span style="font-size:7.5pt;font-family:Optima">, |
|||
activity</font></p> |
|||
< |
2;<o:p> |
||
</o:p> |
|||
<td width="203" height="8"><i><font face="Optima-Oblique" size="1"> |
|||
</span></p> |
|||
<p align="left">In vitro </font></i><font face="Optima" size="1">study;</p> |
|||
<p><span style="font-size:7.5pt;font-family:Optima">55-62.</span></p> |
|||
</td> |
|||
<td width="90" style="width: 67.45pt; padding: .75pt" height="14"> |
|||
</tr> |
|||
<p style="mso-line-height-alt:6.0pt"><span style="font-size:7.5pt;font-family: |
|||
<tr> |
|||
Optima">Effects of dilutions and potencies of cAMP on some enzymatic |
|||
<td width="171" height="8"><b><font face="Optima-Bold" size="1"> |
|||
activities</span></p> |
|||
<p align="left">Contribution to study of the</p> |
|||
</td> |
|||
<p align="left">efficacy of homeopathic potencies</p> |
|||
<td width="84" style="width: 62.9pt; padding: .75pt" height="14"> |
|||
<p align="left">of phosphorus</font></b></p> |
|||
<p><i><span style="font-size:7.5pt;font-family:Optima-Oblique">In vitro </span></i><span style="font-size:7.5pt;font-family:Optima">study;<o:p> |
|||
</td> |
|||
</o:p> |
|||
<td width="128" height="8"><font face="Optima" size="1">Gomez J.C.</font></td> |
|||
</span></p> |
|||
<td width="84" height="8"><i><font face="Optima-Oblique" size="1"> |
|||
<p style="mso-line-height-alt:6.0pt"><span style="font-size:7.5pt;font-family: |
|||
<p align="left">BT, </font></i><b><font face="Optima-Bold" size="1">1999</font></b><font face="Optima" size="1">, |
|||
Optima">basic research</span></p> |
|||
2;</p> |
|||
</td> |
|||
<p align="left">53-57.</font></p> |
|||
</tr> |
|||
<tr style="height:6.0pt"> |
|||
<td width="162" style="width: 121.6pt; padding: .75pt" height="1"> |
|||
<p align="left">Effect of different</p> |
|||
<p><b><span style="font-size:7.5pt;font-family:Optima-Bold">Studies of the |
|||
<p align="left">potencies of</p> |
|||
principles of homeopathy; the changeover from </span><i><span style="font-size:7.5pt;font-family:Optima-BoldOblique">in |
|||
<p align="left">phosphorus</font></p> |
|||
vivo </span></i><span style="font-size:7.5pt;font-family:Optima-Bold">to </span><i><span style="font-size:7.5pt;font-family:Optima-BoldOblique">in |
|||
</td> |
|||
vitro </span></i><span style="font-size:7.5pt;font-family:Optima-Bold">experimental |
|||
<td width="203" height="8"><font face="Optima" size="1"> |
|||
research</span></b></p> |
|||
</td> |
|||
<p align="left">pigs</font></p> |
|||
<td width="121" style="width: 91.05pt; padding: .75pt" height="1"><span style="font-size: 7.5pt; font-family: Optima">Harisch G.,<br> |
|||
</td> |
|||
</ |
Dittmann J.</span></td> |
||
<td width="111" style="width: 83.0pt; padding: .75pt" height="1"> |
|||
<tr> |
|||
<p><i><span style="font-size:7.5pt;font-family:Optima-Oblique">BM, </span></i><b><span style="font-size:7.5pt;font-family:Optima-Bold">1998</span></b><span style="font-size:7.5pt;font-family:Optima">, |
|||
<td width="171" height="8"><b><font face="Optima-Bold" size="1"> |
|||
3;<o:p> |
|||
<p align="left">Determination of the activity of</p> |
|||
</o:p> |
|||
<p align="left">acid phosphatase in the presence</p> |
|||
</span></p> |
|||
<p><span style="font-size:7.5pt;font-family:Optima">98-103.</span></p> |
|||
</td> |
|||
</td> |
|||
<td width="128" height="8"><font face="Optima" size="1"> |
|||
<td width="90" style="width: 67.45pt; padding: .75pt" height="1"> |
|||
<p align="left">Harisch G.,</p> |
|||
<p style="mso-line-height-alt:6.0pt"><span style="font-size:7.5pt;font-family: |
|||
Optima">Potentised and non-potentised dilutions are equally effective, but |
|||
</td> |
|||
have different actions</span></p> |
|||
<td width="84" height="8"><i><font face="Optima-Oblique" size="1"> |
|||
</td> |
|||
<p align="left">BM, </font></i><b><font face="Optima-Bold" size="1">1999</font></b><font face="Optima" size="1">, |
|||
<td width="84" style="width: 62.9pt; padding: .75pt" height="1"> |
|||
4;</p> |
|||
<p style="mso-line-height-alt:6.0pt"><span style="font-size:7.5pt;font-family: |
|||
Optima-Oblique">B</span><span style="font-size:7.5pt;font-family:Optima">asic |
|||
</td> |
|||
research</span></p> |
|||
<td width="92" height="8"><font face="Optima" size="1"> |
|||
</td> |
|||
<p align="left">Effect of enzymatic</p> |
|||
</tr> |
|||
<p align="left">activity of</p> |
|||
<tr style="height:6.0pt"> |
|||
<p align="left">homeopathic</p> |
|||
<td width="162" style="width: 121.6pt; padding: .75pt" height="17"> |
|||
<p align="left">medicine</font></p> |
|||
<p><b><span style="font-size:7.5pt;font-family:Optima-Bold">Determination |
|||
</td> |
|||
of the activity of</span></b> <b><span style="font-size:7.5pt;font-family:Optima-Bold">acid |
|||
<td width="203" height="8"><font face="Optima-Oblique" size="1">B</font><font face="Optima" size="1">asic |
|||
phosphatase with cAMP at</span></b> <b><span style="font-size:7.5pt; |
|||
research</font></td> |
|||
font-family:Optima-Bold">various potencies</span></b></p> |
|||
</tr> |
|||
< |
</td> |
||
<td width="121" style="width: 91.05pt; padding: .75pt" height="17"><span style="font-size: 7.5pt; font-family: Optima">Harisch G.,<br> |
|||
Dittmann J.</span></td> |
|||
<p align="left">Biochemical efficacy of</p> |
|||
<td width="111" style="width: 83.0pt; padding: .75pt" height="17"> |
|||
<p align="left">homeopathic and electronic</p> |
|||
<p class="MsoNormal"><i><span style="font-size:7.5pt;font-family:Optima-Oblique">BM, |
|||
<p align="left">preparations of D8 potassium</p> |
|||
</span></i><b><span style="font-size:7.5pt;font-family:Optima-Bold">1999</span></b><span style="font-size:7.5pt;font-family:Optima">, |
|||
<p align="left">cyanate</font></b></p> |
|||
</ |
1; 4-8.</span></p> |
||
</td> |
|||
<td width="128" height="8"><font face="Optima" size="1"> |
|||
<td width="90" style="width: 67.45pt; padding: .75pt" height="17"> |
|||
<p align="left">Dittmann J.,</p> |
|||
<p style="mso-line-height-alt:6.0pt"><span style="font-size:7.5pt;font-family: |
|||
<p align="left">Kanapin H.,</p> |
|||
Optima">Different effects on</span> <span style="font-size:7.5pt;font-family: |
|||
<p align="left">Harisch G.</font></p> |
|||
Optima">enzymatic activity</span></p> |
|||
</td> |
|||
</td> |
|||
<td width="84" height="8"><i><font face="Optima-Oblique" size="1"> |
|||
<td width="84" style="width: 62.9pt; padding: .75pt" height="17"> |
|||
<p align="left">FKM, </font></i><b><font face="Optima-Bold" size="1">1999</font></b><font face="Optima" size="1">, |
|||
<p><i><span style="font-size:7.5pt;font-family:Optima-Oblique">In vitro </span></i><span style="font-size: 7.5pt; font-family: Optima">study;<br> |
|||
6;</p> |
|||
basic research</span></p> |
|||
</td> |
|||
</tr> |
|||
<td width="92" height="8"><font face="Optima" size="1"> |
|||
<tr style="height:6.0pt"> |
|||
<p align="left">Homeopathic</p> |
|||
<td width="162" style="width: 121.6pt; padding: .75pt" height="18"> |
|||
<p align="left">potentisation is</p> |
|||
<p><b><span style="font-size:7.5pt;font-family:Optima-Bold">Contribution |
|||
<p align="left">more effective than</p> |
|||
to study of the efficacy of homeopathic potencies of phosphorus</span></b></p> |
|||
<p align="left">electronic</p> |
|||
</td> |
|||
<p align="left">potentisation</font></p> |
|||
<td width="121" style="width: 91.05pt; padding: .75pt" height="18"> |
|||
</td> |
|||
< |
<p class="MsoNormal"><span style="font-size:7.5pt;font-family:Optima">Gomez |
||
J.C.</span></p> |
|||
</ |
</td> |
||
<td width="111" style="width: 83.0pt; padding: .75pt" height="18"> |
|||
<tr> |
|||
<p><i><span style="font-size:7.5pt;font-family:Optima-Oblique">BT, </span></i><b><span style="font-size:7.5pt;font-family:Optima-Bold">1999</span></b><span style="font-size:7.5pt;font-family:Optima">, |
|||
<td width="171" height="8"><b><font face="Optima-Bold" size="1"> |
|||
2; 53-57.</span></p> |
|||
<p align="left">Osteoporosis in vitro in rat tibiaderived</p> |
|||
</td> |
|||
<p align="left">osteoblasts is promoted</p> |
|||
<td width="90" style="width: 67.45pt; padding: .75pt" height="18"> |
|||
<p align="left">by the homeopathic preparation,</p> |
|||
<p style="mso-line-height-alt:6.0pt"><span style="font-size:7.5pt;font-family: |
|||
<p align="left">FMS Calciumfluor</font></b></td> |
|||
Optima">Effect of different potencies of phosphorus</span></p> |
|||
<td width="128" height="8"><font face="Optima" size="1"> |
|||
</td> |
|||
<p align="left">Palermo C.,</p> |
|||
<td width="84" style="width: 62.9pt; padding: .75pt" height="18"> |
|||
<p align="left">Filanti C.,</p> |
|||
<p><span style="font-size:7.5pt;font-family:Optima">Tests on guinea</span><span style="font-size:7.5pt;font-family: |
|||
<p align="left">Poggi S.,</p> |
|||
Optima"> pigs</span></p> |
|||
</td> |
|||
<td width="84" height="8"><i><font face="Optima-Oblique" size="1"> |
|||
</tr> |
|||
<p align="left">Cell Biol Int</font></i><font face="Optima" size="1">, </font><b><font face="Optima-Bold" size="1">1999</font></b><font face="Optima" size="1">,</p> |
|||
<tr style="height:6.0pt"> |
|||
<p align="left">23(1): 31-40.</font></td> |
|||
<td width="162" style="width: 121.6pt; padding: .75pt" height="25"> |
|||
<p><b><span style="font-size:7.5pt;font-family:Optima-Bold">Determination |
|||
<p align="left">Stimulant</font></b></td> |
|||
of the activity of acid phosphatase in the presence of Ubichinon comp.</span></b></p> |
|||
<td width="203" height="8"><font face="Optima" size="1"> |
|||
</td> |
|||
<p align="left">Osteogenesis</p> |
|||
<td width="121" style="width: 91.05pt; padding: .75pt" height="25"><span style="font-size: 7.5pt; font-family: Optima">Harisch G.,<br> |
|||
<p align="left">(trial with</p> |
|||
Dittmann J.</span></td> |
|||
<td width="111" style="width: 83.0pt; padding: .75pt" height="25"> |
|||
</tr> |
|||
<p><i><span style="font-size:7.5pt;font-family:Optima-Oblique">BM, </span></i><b><span style="font-size:7.5pt;font-family:Optima-Bold">1999</span></b><span style="font-size:7.5pt;font-family:Optima">, |
|||
<tr> |
|||
4; 188-194.</span></p> |
|||
<td width="171" height="32" rowspan="2"><b><font face="Optima-Bold" size="1"> |
|||
</td> |
|||
<p align="left">Thin-layer chromatography (TLC)</p> |
|||
<td width="90" style="width: 67.45pt; padding: .75pt" height="25"> |
|||
<p align="left">of homeopathic active</p> |
|||
<p style="mso-line-height-alt:6.0pt"><span style="font-size:7.5pt;font-family: |
|||
<p align="left">constituents</font></b></td> |
|||
Optima">Effect of enzymatic activity of homeopathic medicine</span></p> |
|||
<td width="128" height="32" rowspan="2"><font face="Optima" size="1">Schmolz |
|||
</td> |
|||
<td width="84" style="width: 62.9pt; padding: .75pt" height="25"> |
|||
<p class="MsoNormal" style="mso-line-height-alt:6.0pt"><span style="font-size: |
|||
<p align="left">BM, </font></i><b><font face="Optima-Bold" size="1">1999</font></b><font face="Optima" size="1">, |
|||
7.5pt;font-family:Optima-Oblique">B</span><span style="font-size:7.5pt; |
|||
5;</p> |
|||
font-family:Optima">asic research</span></p> |
|||
</td> |
|||
<td width="92" height="16"><font face="Optima" size="1"> |
|||
</tr> |
|||
<p align="left">Constituents of</font> <font face="Optima" size="1">Arnica |
|||
<tr style="height:6.0pt"> |
|||
comp.-</font> <font face="Optima" size="1">Heel® ointment:</font> <font face="Optima" size="1">electrophoresis</font> |
|||
<td width="162" style="width: 121.6pt; padding: .75pt" height="21"> |
|||
<p><b><span style="font-size:7.5pt;font-family:Optima-Bold">Biochemical |
|||
penetration.</font> </td> |
|||
efficacy of homeopathic and electronic preparations of D8 potassiumcyanate</span></b></p> |
|||
<td width="203" height="32"><font face="Optima" size="1">Basic research</font></td> |
|||
</ |
</td> |
||
<td width="121" style="width: 91.05pt; padding: .75pt" height="21"><span style="font-size: 7.5pt; font-family: Optima">Dittmann J.,<br> |
|||
<tr> |
|||
Kanapin H.,<br> |
|||
<td width="92" height="16"><font face="Optima" size="1">Effect of</font> <font face="Optima" size="1">homeopathic</font> |
|||
Harisch G.</span></td> |
|||
<font face="Optima" size="1">constituents on</font> <font face="Optima" size="1">enzymatic |
|||
<td width="111" style="width: 83.0pt; padding: .75pt" height="21"> |
|||
activity.</font></td> |
|||
<p><i><span style="font-size:7.5pt;font-family:Optima-Oblique">FKM, </span></i><b><span style="font-size:7.5pt;font-family:Optima-Bold">1999</span></b><span style="font-size:7.5pt;font-family:Optima">, |
|||
<td width="203" height="4"><font face="Optima" size="1">Basic research</font></td> |
|||
</ |
6; 15-18.</span></p> |
||
< |
</td> |
||
<td width="90" style="width: 67.45pt; padding: .75pt" height="21"> |
|||
<p style="mso-line-height-alt:6.0pt"><span style="font-size:7.5pt;font-family: |
|||
<p align="left">Efficacy of a potentised</p> |
|||
Optima">Homeopathic potentisation is more effective than electronic |
|||
<p align="left">homeopathic drug in reducing</p> |
|||
potentisation</span></p> |
|||
<p align="left">cytotoxic effects produced by</p> |
|||
</td> |
|||
<p align="left">arsenic trioxide in mice</font></b></td> |
|||
<td width="84" style="width: 62.9pt; padding: .75pt" height="21"> |
|||
<p class="MsoNormal" style="mso-line-height-alt:6.0pt"><span style="font-size: |
|||
<p align="left">Datta S.,</p> |
|||
7.5pt;font-family:Optima-Oblique">B</span><span style="font-size:7.5pt; |
|||
<p align="left">Mallick P.,</p> |
|||
font-family:Optima">asic research</span></p> |
|||
</td> |
|||
<td width="84" height="8"><i><font face="Optima-Oblique" size="1"> |
|||
</tr> |
|||
<p align="left">Complement Ther</p> |
|||
<tr style="height:6.0pt"> |
|||
<p align="left">Med</font></i><font face="Optima" size="1">, </font><b><font face="Optima-Bold" size="1">1999 |
|||
<td width="162" style="width: 121.6pt; padding: .75pt" height="11"> |
|||
</font></b><font face="Optima" size="1">Jan;</p> |
|||
<p><b><span style="font-size:7.5pt;font-family:Optima-Bold">Osteoporosis |
|||
in vitro in rat tibia derived osteoblasts is promoted by the homeopathic |
|||
<td width="92" height="8"><b><font face="Optima-Bold" size="1">Protective</font></b></td> |
|||
preparation, FMS Calciumfluor</span></b></p> |
|||
<td width="203" height="8"><font face="Optima" size="1"> |
|||
</td> |
|||
<p align="left">Arsenic trioxide</p> |
|||
<td width="121" style="width: 91.05pt; padding: .75pt" height="11"><span style="font-size: 7.5pt; font-family: Optima">Palermo C.,<br> |
|||
<p align="left">toxicity</font></td> |
|||
< |
Filanti C.,<br> |
||
< |
Poggi S.,<br> |
||
Manduca P.</span></td> |
|||
<td width="171" height="8"><b><font face="Optima-Bold" size="1"> |
|||
<td width="111" style="width: 83.0pt; padding: .75pt" height="11"> |
|||
<p align="left">Efficacy of a potentised</p> |
|||
<p><i><span style="font-size:7.5pt;font-family:Optima-Oblique">Cell Biol |
|||
<p align="left">homeopathic drug in reducing</p> |
|||
Int</span></i><span style="font-size:7.5pt;font-family:Optima">, </span><b><span style="font-size:7.5pt;font-family:Optima-Bold">1999</span></b><span style="font-size:7.5pt;font-family:Optima">,<o:p> |
|||
<p align="left">cytotoxic effects produced by</p> |
|||
</o:p> |
|||
<p align="left">arsenic trioxide in mice</font></b></td> |
|||
</span></p> |
|||
<td width="128" height="8"><font face="Optima" size="1"> |
|||
<p><span style="font-size:7.5pt;font-family:Optima">23(1): 31-40.</span></p> |
|||
</td> |
|||
<p align="left">Mallick P.,</p> |
|||
<td width="90" style="width: 67.45pt; padding: .75pt" height="11"> |
|||
<p align="left">Bukhsh A.R.</font></td> |
|||
< |
<p style="mso-line-height-alt:6.0pt"><b><span style="font-size:7.5pt; |
||
font-family:Optima-Bold">Stimulant</span></b></p> |
|||
<p align="left">Complement Ther</p> |
|||
</td> |
|||
<p align="left">Med</font></i><font face="Optima" size="1">, </font><b><font face="Optima-Bold" size="1">1999 |
|||
<td width="84" style="width: 62.9pt; padding: .75pt" height="11"><span style="font-size: 7.5pt; font-family: Optima">Osteogenesis<br> |
|||
</font></b><font face="Optima" size="1">Sep;</p> |
|||
(trial with<br> |
|||
<p align="left">7 (3): 156-63 </font><b><font face="Optima-Bold" size="1">(b).</font></b></td> |
|||
compound drug)</span></td> |
|||
<td width="92" height="8"><b><font face="Optima-Bold" size="1">Protective</font></b></td> |
|||
</tr> |
|||
<td width="203" height="8"><font face="Optima" size="1"> |
|||
<tr style="height:24.0pt"> |
|||
<p align="left">Arsenic trioxide</p> |
|||
<td width="162" rowspan="2" style="width: 121.6pt; padding: .75pt" height="34"> |
|||
<p align="left">toxicity</font></td> |
|||
<p><b><span style="font-size:7.5pt;font-family:Optima-Bold">Thin-layer |
|||
</tr> |
|||
chromatography (TLC) of homeopathic active constituents</span></b></p> |
|||
<tr> |
|||
</td> |
|||
<td width="171" height="8"><font face="Optima-Bold" size="1"><b> |
|||
<td width="121" rowspan="2" style="width: 91.05pt; padding: .75pt" height="34"> |
|||
<p align="left">Non-cytotoxic antiviral action of</b></font> <font face="Optima-Bold" size="1"><b>a |
|||
<p class="MsoNormal"><span style="font-size:7.5pt;font-family:Optima">Schmolz |
|||
homeopathic drug</b></font></td> |
|||
M.</span></p> |
|||
<td width="128" height="8"><font face="Optima" size="1">Heine H.</font></td> |
|||
</td> |
|||
<td width="84" height="8"><i><font face="Optima-Oblique" size="1"> |
|||
<td width="111" rowspan="2" style="width: 83.0pt; padding: .75pt" height="34"> |
|||
<p align="left">Ärzteitschrift für</p> |
|||
<p><i><span style="font-size:7.5pt;font-family:Optima-Oblique">BM, </span></i><b><span style="font-size:7.5pt;font-family:Optima-Bold">1999</span></b><span style="font-size:7.5pt;font-family:Optima">, |
|||
<p align="left">Neturheilverfahre</font></i><font face="Optima" size="1">,</p> |
|||
5;<o:p> |
|||
</font><b><font face="Optima-Bold" size="1"> |
|||
</o:p> |
|||
<p align="left">2000</font></b><font face="Optima" size="1">; 41: 542-7.</font></td> |
|||
</span></p> |
|||
<td width="92" height="8"><b><font face="Optima-Bold" size="1">Stimulant</font></b></td> |
|||
<p><span style="font-size:7.5pt;font-family:Optima">248-250.</span></p> |
|||
<td width="203" height="8"><font face="Symbol" size="1"> |
|||
</td> |
|||
<p align="left">ã </font><font face="Optima" size="1">interferon</p> |
|||
<td width="90" style="width: 67.45pt; padding: .75pt" height="67"> |
|||
<p align="left">synthesis</font></td> |
|||
<p><span style="font-size:7.5pt;font-family:Optima">Constituents of</span> |
|||
</tr> |
|||
<span style="font-size:7.5pt;font-family:Optima">Arnica comp.-</span> <span style="font-size:7.5pt;font-family:Optima">Heel® |
|||
<tr> |
|||
ointment:</span> <span style="font-size:7.5pt;font-family:Optima">electrophoresis</span> |
|||
<td width="171" height="8"><b><font face="Optima-Bold" size="1"> |
|||
<span style="font-size:7.5pt;font-family:Optima">accelerates their</span> <span style="font-size:7.5pt;font-family:Optima">skin |
|||
<p align="left">Efficacy of a potentised</p> |
|||
penetration.</span></p> |
|||
<p align="left">homeopathic drug in reducing</p> |
|||
</td> |
|||
<p align="left">cytotoxic effects produced by</p> |
|||
<td width="84" style="width: 62.9pt; padding: .75pt" height="67"> |
|||
<p align="left">arsenic trioxide in mice</font></b></td> |
|||
< |
<p class="MsoNormal"><span style="font-size:7.5pt;font-family:Optima">Basic |
||
research</span></p> |
|||
</td> |
|||
<p align="left">Mitra K.,</p> |
|||
</tr> |
|||
<p align="left">Khuda</p> |
|||
<tr style="height:3.0pt"> |
|||
<p align="left">Bukhsh A.R.</font></td> |
|||
<td width="90" style="width: 67.45pt; padding: .75pt" height="1"> |
|||
<p class="MsoNormal"><span style="font-size:7.5pt;font-family:Optima">Effect |
|||
<p align="left">Complement Ther</p> |
|||
of</span> <span style="font-size:7.5pt;font-family:Optima">homeopathic</span> |
|||
<span style="font-size:7.5pt;font-family:Optima">constituents on</span> <span style="font-size:7.5pt;font-family:Optima">enzymatic |
|||
</font></b><font face="Optima" size="1">Sep;</p> |
|||
activity.</span></p> |
|||
</td> |
|||
<td width="92" height="8"><b><font face="Optima-Bold" size="1">Protective</font></b></td> |
|||
<td width="84" style="width: 62.9pt; padding: .75pt" height="1"> |
|||
<p class="MsoNormal" style="mso-line-height-alt:3.0pt"><span style="font-size: |
|||
<p align="left">Arsenic trioxide</p> |
|||
7.5pt;font-family:Optima">Basic research</span></p> |
|||
<p align="left">toxicity</font></td> |
|||
</ |
</td> |
||
</tr> |
|||
<tr style="height:6.0pt"> |
|||
<td width="171" height="8"><b><font face="Optima-Bold" size="1"> |
|||
<td width="162" style="width: 121.6pt; padding: .75pt" height="35"> |
|||
<p align="left">Stimulatory effect of some plant</p> |
|||
<p><b><span style="font-size:7.5pt;font-family:Optima-Bold">Efficacy of a |
|||
<p align="left">extracts used in homeopathy on</p> |
|||
potentised homeopathic drug in reducing cytotoxic effects produced by |
|||
<p align="left">the phagocytosis induced</p> |
|||
arsenic trioxide in mice</span></b></p> |
|||
</td> |
|||
<p align="left">polymorphonuclear leukocytes</font></b></td> |
|||
<td width="121" style="width: 91.05pt; padding: .75pt" height="35"><span style="font-size: 7.5pt; font-family: Optima">Datta S.,<br> |
|||
Mallick P.,<br> |
|||
< |
Khuda Bukhsh A.R.</span></td> |
||
<td width="111" style="width: 83.0pt; padding: .75pt" height="35"> |
|||
<p align="left">Olinescu R.</font></td> |
|||
< |
<p><i><span style="font-size:7.5pt;font-family:Optima-Oblique">Complement Ther<br> |
||
Med</span></i><span style="font-size:7.5pt;font-family:Optima">, </span><b><span style="font-size:7.5pt;font-family:Optima-Bold">1999</span></b><span style="font-size:7.5pt;font-family:Optima">Jan;<br> |
|||
<p align="left">Rocz Akad Med</p> |
|||
7 (8): 62-75 </span><b><span style="font-size:7.5pt;font-family:Optima-Bold">(a).</span></b></p> |
|||
</td> |
|||
<p align="left">45: 246-254.</font></td> |
|||
<td width="90" style="width: 67.45pt; padding: .75pt" height="35"> |
|||
<p class="MsoNormal" style="mso-line-height-alt:6.0pt"><b><span style="font-size:7.5pt;font-family:Optima-Bold">Protective</span></b></p> |
|||
<td width="203" height="8"><font face="Optima" size="1"> |
|||
</td> |
|||
<p align="left">Phagocytosis</font></td> |
|||
<td width="84" style="width: 62.9pt; padding: .75pt" height="35"><span style="font-size: 7.5pt; font-family: Optima">Arsenic trioxide<br> |
|||
</tr> |
|||
< |
toxicity</span></td> |
||
</tr> |
|||
<td width="171" height="8"><b><font face="Optima-Bold" size="1"> |
|||
<tr style="height:6.0pt"> |
|||
<p align="left">Difference between the efficacy</p> |
|||
<td width="162" style="width: 121.6pt; padding: .75pt" height="32"> |
|||
<p align="left">of single potencies and chords</font></b></td> |
|||
<p><b><span style="font-size:7.5pt;font-family:Optima-Bold">Efficacy of a |
|||
<td width="128" height="8"><font face="Optima" size="1"> |
|||
potentised homeopathic drug in reducing cytotoxic effects produced by |
|||
<p align="left">Dittmann J.,</p> |
|||
arsenic trioxide in mice</span></b></p> |
|||
</td> |
|||
<td width="84" height="8"><i><font face="Optima-Oblique" size="1"> |
|||
<td width="121" style="width: 91.05pt; padding: .75pt" height="32"><span style="font-size: 7.5pt; font-family: Optima">Datta S.,<br> |
|||
Mallick P.,<br> |
|||
Khuda Bukhsh A.R.</span></td> |
|||
<td width="111" style="width: 83.0pt; padding: .75pt" height="32"> |
|||
<p><i><span style="font-size:7.5pt;font-family:Optima-Oblique">Complement |
|||
<p align="left">Potency chords are</p> |
|||
Ther<br> |
|||
<p align="left">more effective than</p> |
|||
Med</span></i><span style="font-size:7.5pt;font-family:Optima">, </span><b><span style="font-size:7.5pt;font-family:Optima-Bold">1999 |
|||
<p align="left">single potencies</font></td> |
|||
</span></b><span style="font-size:7.5pt;font-family:Optima">Sep;<br> |
|||
<td width="203" height="8"><font face="Optima" size="1">Basic research</font></td> |
|||
7 (3): 156-63 </span><b><span style="font-size:7.5pt;font-family:Optima-Bold">(b).</span></b></p> |
|||
</tr> |
|||
< |
</td> |
||
<td width="90" style="width: 67.45pt; padding: .75pt" height="32"> |
|||
<p class="MsoNormal" style="mso-line-height-alt:6.0pt"><b><span style="font-size:7.5pt;font-family:Optima-Bold">Protective</span></b></p> |
|||
<p align="left">Influence of some homeopathic</p> |
|||
</td> |
|||
<p align="left">drugs on the catalytic activity of</p> |
|||
<td width="84" style="width: 62.9pt; padding: .75pt" height="32"><span style="font-size: 7.5pt; font-family: Optima">Arsenic trioxide<br> |
|||
<p align="left">uricase, acid phosphatase and the</p> |
|||
toxicity</span></td> |
|||
<p align="left">cytosol glutathion-S-transferase</font></b></td> |
|||
</tr> |
|||
<td width="128" height="28"><font face="Optima" size="1"> |
|||
<tr style="height:6.0pt"> |
|||
<p align="left">Dittmann J.,</p> |
|||
<td width="162" style="width: 121.6pt; padding: .75pt" height="17"> |
|||
<p align="left">Kanapin H.,</p> |
|||
<p><b><span style="font-size:7.5pt;font-family:Optima-Bold">Non-cytotoxic |
|||
<p align="left">Harisch G.</font></td> |
|||
antiviral action of</span></b> <b><span style="font-size:7.5pt;font-family: |
|||
Optima-Bold">a homeopathic drug</span></b></p> |
|||
<p align="left">BM, </font></i><b><font face="Optima-Bold" size="1">2000</font></b><font face="Optima" size="1">, |
|||
</td> |
|||
<td width="121" style="width: 91.05pt; padding: .75pt" height="17"> |
|||
<p align="left">125-131</font></td> |
|||
< |
<p class="MsoNormal"><span style="font-size:7.5pt;font-family:Optima">Heine |
||
H.</span></p> |
|||
</td> |
|||
<p align="left">potencies on three</p> |
|||
<td width="111" style="width: 83.0pt; padding: .75pt" height="17"> |
|||
<p align="left">different enzymatic</p> |
|||
<p><i><span style="font-size:7.5pt;font-family:Optima-Oblique">Ärzteitschrift |
|||
<p align="left">systems</font></td> |
|||
fü</span></i><i><span style="font-size:7.5pt;font-family:Optima-Oblique">rNeturheilverfahre, |
|||
<td width="203" height="28"><font face="Optima" size="1">Basic research</font></td> |
|||
</span></i><b><span style="font-size:7.5pt;font-family:Optima-Bold">2000</span></b><span style="font-size:7.5pt;font-family:Optima">; |
|||
</tr> |
|||
< |
41: 542-7.</span></p> |
||
</td> |
|||
<td width="171" height="37"><b><font face="Optima-Bold" size="1"> |
|||
<td width="90" style="width: 67.45pt; padding: .75pt" height="17"> |
|||
<p align="left">Influence of some homeopathic</p> |
|||
<p class="MsoNormal" style="mso-line-height-alt:6.0pt"><b><span style="font-size:7.5pt;font-family:Optima-Bold">Stimulant</span></b></p> |
|||
<p align="left">drugs on the catalytic activity of</p> |
|||
</td> |
|||
<p align="left">cAMP-dependent protein kinases</font></b></td> |
|||
<td width="84" style="width: 62.9pt; padding: .75pt" height="17"> |
|||
<p><span style="font-size:7.5pt;font-family:Symbol">ã </span><span style="font-size:7.5pt;font-family:Optima">interferon<o:p> |
|||
<p align="left">Dittmann J.,</p> |
|||
</o:p> |
|||
</span></p> |
|||
< |
<p style="mso-line-height-alt:6.0pt"><span style="font-size:7.5pt;font-family: |
||
Optima">synthesis</span></p> |
|||
<p align="left">BM, </font></i><b><font face="Optima-Bold" size="1">2000</font></b><font face="Optima" size="1">, |
|||
</td> |
|||
</tr> |
|||
<p align="left">289-296.</font></td> |
|||
<tr style="height:6.0pt"> |
|||
<td width="162" style="width: 121.6pt; padding: .75pt" height="42"> |
|||
<p align="left">Effect of different</p> |
|||
<p><b><span style="font-size:7.5pt;font-family:Optima-Bold">Efficacy of a |
|||
<p align="left">potencies of 5</p> |
|||
potentised homeopathic drug in reducing cytotoxic effects produced by |
|||
<p align="left">substances on</p> |
|||
arsenic trioxide in mice</span></b></p> |
|||
</td> |
|||
<td width="203" height="37"><font face="Optima" size="1">Basic research</font></td> |
|||
<td width="121" style="width: 91.05pt; padding: .75pt" height="42"><span style="font-size: 7.5pt; font-family: Optima">Kundu S.N.,<br> |
|||
</tr> |
|||
< |
Mitra K.,<br> |
||
Khuda Bukhsh A.R.</span></td> |
|||
<td width="171" height="38"><b><font face="Optima-Bold" size="1"> |
|||
<td width="111" style="width: 83.0pt; padding: .75pt" height="42"> |
|||
<p align="left">Neuroprotection from glutamate</p> |
|||
<p><i><span style="font-size:7.5pt;font-family:Optima-Oblique">Complement |
|||
<p align="left">toxicity with ultra-low dose</p> |
|||
Ther<br> |
|||
<p align="left">glutamate</font></b></td> |
|||
Med </span></i><span style="font-size:7.5pt;font-family:Optima">, </span><b><span style="font-size:7.5pt;font-family:Optima-Bold">2000 |
|||
<td width="128" height="38"> |
|||
</span></b><span style="font-size:7.5pt;font-family:Optima">Sep;<br> |
|||
< |
1 (3): 157-65.</span></p> |
||
</td> |
|||
<p align="left">Zortella F.</font></td> |
|||
<td width="90" style="width: 67.45pt; padding: .75pt" height="42"> |
|||
<p class="MsoNormal" style="mso-line-height-alt:6.0pt"><b><span style="font-size:7.5pt;font-family:Optima-Bold">Protective</span></b></p> |
|||
<p align="left">Neuroreport</font></i><font face="Optima" size="1">,</p> |
|||
</td> |
|||
</font><b><font face="Optima-Bold" size="1"> |
|||
<td width="84" style="width: 62.9pt; padding: .75pt" height="42"><span style="font-size: 7.5pt; font-family: Optima">Arsenic trioxide<br> |
|||
<p align="left">2001 </font></b><font face="Optima" size="1">Feb 92; 12</p> |
|||
toxicity</span></td> |
|||
</tr> |
|||
<td width="92" height="38"><b><font face="Optima-Bold" size="1">Protective</font></b></td> |
|||
<tr style="height:6.0pt"> |
|||
<td width="203" height="38"><font face="Optima" size="1">Glutamate |
|||
<td width="162" style="width: 121.6pt; padding: .75pt" height="32"> |
|||
toxicity</font></td> |
|||
<p><b><span style="font-size:7.5pt;font-family:Optima-Bold">Stimulatory |
|||
</tr> |
|||
effect of some plant extracts used in homeopathy on the phagocytosis |
|||
</table> |
|||
induced chemiluminescence of polymorphonuclear leukocytes</span></b></p> |
|||
</div> |
|||
</td> |
|||
<font face="Optima" size="1"> |
|||
<td width="121" style="width: 91.05pt; padding: .75pt" height="32"><span style="font-size: 7.5pt; font-family: Optima">Crocnan D.,<br> |
|||
<p align="left"> </p> |
|||
Greabu M.,<br> |
|||
<p align="left">KEY: BT = Biomedical Therapy</p> |
|||
Olinescu R.</span></td> |
|||
<p align="left">BM = Biologische Medizin</p> |
|||
<td width="111" style="width: 83.0pt; padding: .75pt" height="32"> |
|||
<p align="left">FKM = Forschung Komplementär Medizin</p> |
|||
<p><i><span style="font-size:7.5pt;font-family:Optima-Oblique">Rocz Akad Med<br> |
|||
</font></font></font></font></font></font></font></font>[[User:Ramaanand|Ramaanand]] ([[User talk:Ramaanand|talk]]) 02:14, 17 March 2008 (UTC)Dr.Jhingadé |
|||
Biochemist</span></i><span style="font-size:7.5pt;font-family:Optima">, </span><b><span style="font-size:7.5pt;font-family:Optima-Bold">200</span></b><span style="font-size: 7.5pt"><b>0;</b><br> |
|||
45: 246-254.</span></p> |
|||
</td> |
|||
<td width="90" style="width: 67.45pt; padding: .75pt" height="32"> |
|||
<p class="MsoNormal" style="mso-line-height-alt:6.0pt"><b><span style="font-size:7.5pt;font-family:Optima-Bold">Stimulant</span></b></p> |
|||
</td> |
|||
<td width="84" style="width: 62.9pt; padding: .75pt" height="32"> |
|||
<p style="mso-line-height-alt:6.0pt"><span style="font-size:7.5pt;font-family: |
|||
Optima">Phagocytosis</span></p> |
|||
</td> |
|||
</tr> |
|||
<tr style="height:6.0pt"> |
|||
<td width="162" style="width: 121.6pt; padding: .75pt" height="16"> |
|||
<p><b><span style="font-size:7.5pt;font-family:Optima-Bold">Difference |
|||
between the efficacy of single potencies and chords</span></b></p> |
|||
</td> |
|||
<td width="121" style="width: 91.05pt; padding: .75pt" height="16"><span style="font-size: 7.5pt; font-family: Optima">Dittmann J.,<br> |
|||
Harisch G.</span></td> |
|||
<td width="111" style="width: 83.0pt; padding: .75pt" height="16"> |
|||
<p><i><span style="font-size:7.5pt;font-family:Optima-Oblique">BM, </span></i><b><span style="font-size:7.5pt;font-family:Optima-Bold">2000</span></b><span style="font-size:7.5pt;font-family:Optima">, |
|||
1; 18-23.</span></p> |
|||
</td> |
|||
<td width="90" style="width: 67.45pt; padding: .75pt" height="16"> |
|||
<p style="mso-line-height-alt:6.0pt"><span style="font-size:7.5pt;font-family: |
|||
Optima">Potency chords are more effective than single potencies</span></p> |
|||
</td> |
|||
<td width="84" style="width: 62.9pt; padding: .75pt" height="16"> |
|||
<p class="MsoNormal" style="mso-line-height-alt:6.0pt"><span style="font-size: |
|||
7.5pt;font-family:Optima">Basic research</span></p> |
|||
</td> |
|||
</tr> |
|||
<tr style="height:21.0pt"> |
|||
<td width="162" style="width: 121.6pt; padding: .75pt" height="1"> |
|||
<p><b><span style="font-size:7.5pt;font-family:Optima-Bold">Influence of |
|||
some homeopathic drugs on the catalytic activity of uricase, acid |
|||
phosphatase and the cytosol glutathion-S-transferase</span></b></p> |
|||
</td> |
|||
<td width="121" style="width: 91.05pt; padding: .75pt" height="1"> |
|||
<p><span style="font-size: 7.5pt; font-family: Optima">Dittmann J.,<br> |
|||
Kanapin H.,<br> |
|||
Harisch G.</span></p> |
|||
</td> |
|||
<td width="111" style="width: 83.0pt; padding: .75pt" height="1"> |
|||
<p><i><span style="font-size:7.5pt;font-family:Optima-Oblique">BM, </span></i><b><span style="font-size:7.5pt;font-family:Optima-Bold">2000</span></b><span style="font-size:7.5pt;font-family:Optima">, |
|||
3;<o:p> |
|||
</o:p> |
|||
</span></p> |
|||
<p><span style="font-size:7.5pt;font-family:Optima">125-131</span></p> |
|||
</td> |
|||
<td width="90" style="width: 67.45pt; padding: .75pt" height="1"> |
|||
<p><span style="font-size:7.5pt;font-family:Optima">Effect of D8 potencies |
|||
on three different enzymatic systems</span></p> |
|||
</td> |
|||
<td width="84" style="width: 62.9pt; padding: .75pt" height="1"> |
|||
<p class="MsoNormal"><span style="font-size:7.5pt;font-family:Optima">Basic |
|||
research</span></p> |
|||
</td> |
|||
</tr> |
|||
<tr style="height:27.75pt"> |
|||
<td width="162" style="width: 121.6pt; padding: .75pt" height="17"> |
|||
<p><b><span style="font-size:7.5pt;font-family:Optima-Bold">Influence of |
|||
some homeopathic drugs on the catalytic activity of cAMP-dependent protein |
|||
kinases</span></b></p> |
|||
</td> |
|||
<td width="121" style="width: 91.05pt; padding: .75pt" height="17"><span style="font-size: 7.5pt; font-family: Optima">Dittmann J.,<br> |
|||
Kanapin H.,<br> |
|||
Harisch G.</span></td> |
|||
<td width="111" style="width: 83.0pt; padding: .75pt" height="17"> |
|||
<p><i><span style="font-size:7.5pt;font-family:Optima-Oblique">BM, </span></i><b><span style="font-size:7.5pt;font-family:Optima-Bold">2000</span></b><span style="font-size:7.5pt;font-family:Optima">, |
|||
6;<o:p> |
|||
</o:p> |
|||
</span></p> |
|||
<p><span style="font-size:7.5pt;font-family:Optima">289-296.</span></p> |
|||
</td> |
|||
<td width="90" style="width: 67.45pt; padding: .75pt" height="17"> |
|||
<p><span style="font-size:7.5pt;font-family:Optima">Effect of different |
|||
potencies of 5 substances on enzymatic activity</span></p> |
|||
</td> |
|||
<td width="84" style="width: 62.9pt; padding: .75pt" height="17"> |
|||
<p class="MsoNormal"><span style="font-size:7.5pt;font-family:Optima">Basic |
|||
research</span></p> |
|||
</td> |
|||
</tr> |
|||
<tr style="height:28.5pt"> |
|||
<td width="162" style="width: 121.6pt; padding: .75pt" height="1"> |
|||
<p><b><span style="font-size:7.5pt;font-family:Optima-Bold">Neuroprotection |
|||
from glutamate toxicity with ultra-low dose glutamate</span></b></p> |
|||
</td> |
|||
<td width="121" style="width: 91.05pt; padding: .75pt" height="1"><span style="font-size: 7.5pt; font-family: Optima">Jonas W.,<br> |
|||
Lin Y.,<br> |
|||
Zortella F.</span></td> |
|||
<td width="111" style="width: 83.0pt; padding: .75pt" height="1"> |
|||
<p><i><span style="font-size:7.5pt;font-family:Optima-Oblique">Neuroreport,<br> |
|||
</span></i><b><span style="font-size:7.5pt;font-family:Optima-Bold">2001 </span></b><span style="font-size:7.5pt;font-family:Optima">Feb |
|||
92; 1</span><span style="font-size: 7.5pt; font-family: Optima">2<br> |
|||
(2): 335-9.</span></p> |
|||
</td> |
|||
<td width="90" style="width: 67.45pt; padding: .75pt" height="1"> |
|||
<p class="MsoNormal"><b><span style="font-size:7.5pt;font-family:Optima-Bold">Protective</span></b></p> |
|||
</td> |
|||
<td width="84" style="width: 62.9pt; padding: .75pt" height="1"> |
|||
<p class="MsoNormal"><span style="font-size:7.5pt;font-family:Optima">Glutamate |
|||
toxicity</span></p> |
|||
</td> |
|||
</tr> |
|||
</table> |
|||
<p><b><span style="font-size:7.5pt;font-family:Optima"> KEY: BT = |
|||
Biomedical Therapy</span></b></p> |
|||
<p><b><span style="font-size:7.5pt;font-family:Optima">BM = Biologische Medizin</span></b></p> |
|||
<p><b><span style="font-size:7.5pt;font-family:Optima">FKM = Forschung |
|||
Komplementär Medizin</span></b></p> |
|||
==wikified version of the table== |
==wikified version of the table== |
Revision as of 02:55, 23 March 2008
Dear Tim,
Please put this on the Talk:Homeopathy Page and mention it is posted by me (or else the others may think I've bribed you); I'm not yet able to post there directly myself because the Page is semi-writeprotected.
Here are some of the studies/clinical trials:-
STUDIES OF THE ACTIVITY OF HOMEOPATHIC MEDICINES
ORIGINAL/TRANSLATED TITLE |
AUTHOR(S) |
PUBLICATION |
ACTIVITY |
STUDY |
Inhibition of
lymphoblast |
Colas H., |
Ann. Homéopat.<o:p> </o:p> Fr., 1975, 6: 1-11. |
Inhibitory |
Lymphoblast<o:p> </o:p> transformation |
Inquiry into the limits of biological effects of chemical compounds in tissue culture. I. Low dose effects of mercuric chloride |
Mansvelt J.D., van Amons E. |
Z.
Naturtorschung,<o:p>
</o:p>
|
Inhibitory |
Lymphocyte<o:p> </o:p> growth |
The effects of Belladonna and Ferrum phosphoricum on the chemoluminescence of human poly-morphonuclear neutrophils |
Poitevin B.,Aubin M.,Royer J.F. |
Ann. Homéop. Fr.,<o:p> </o:p> 1983, 3: 5-12. |
Inhibitory |
Radical release |
Effect of aconitum and veratrum on the isolated perfused heart of the common eel (Anguilla anguilla) |
Pennec J.P., Aubin M. |
Comp.
Biochem.<o:p>
</o:p>
|
Protective |
Aconitine toxicity |
Elements of homeopathic pharmacology |
Aubin M. |
Homéopathie Franç., 1984, 72:231- 235 |
Protective |
Aconitine toxicity |
The effect of homeopathic preparations on the phagocyte activity of granulocytes. In vitro tests and double-blind controlled trials |
Wagner H.,Jurcic K.,Behrens N. |
Arzneim. |
Stimulant |
Phagocytosis |
Approach to quantitative analysis of the effect of Apis mellifica on the degranulation of human basophils cultivated in vitro |
Poitevin B.,Aubin M.,Benveniste J. |
Innov.
Tech. Biol. |
Inhibitory |
Basophil<o:p> </o:p> degranulation |
In vitro stimulation of human granulocytes and lymphocytes by pico- and femtogram quantities of cytostatic agents |
Wagner H.,Kreher B.,Jurcic K. |
Arzneim. Forsch./Drug Res., 1988, 38: 273-275. |
Stimulant |
Lymphocyte<o:p> </o:p> growth |
Human basophil degranulation triggered by very dilute antiserum against IgE |
Davenas E., Beauvais F., Amara J., Robinson M., Miadonna A., Tedeschi A., Pomeranz B., Fortner P., Belon P., Sainte-Laudy J., Poitevin B., Benveniste J. |
Nature, 1988,<o:p> </o:p> 333: 816-818. |
Stimulant |
Basophils |
In vitro immunological degranulation of human basophils is modulated by lung histamine and Apis mellifica |
Poitevin B.,Davenas E.,Benveniste J. |
Brit. J. Clin. |
Inhibitory |
Basophil degranulation |
Cytotoxic agents as immunomodulators |
Wagner H., Kreher B. |
Proc. of
the 3rd |
Stimulant |
Lymphocyte<o:p> </o:p> growth |
Contributions of fundamental research in homeopathy |
Boiron J., Belon P. |
Berl. J.
Res. Hom., |
Inhibitory |
Basophil degranulation |
Synergism of action between indoleacetic acid (IAA) and highlydiluted solutions of CaCO3 on the growth of oat coleoptiles |
Bornoroni C. |
Berl. J.
Res. Hom., |
Stimulant |
Growth of plant cells |
Study of the action of Hahnemannian dilutions of mercury chloride on the mitotic index in animal cell cultures. |
Boiron J.,Abecassis J.,Bernard A.M. |
Ann. Homéop.Fr., 1991, 23:<o:p> </o:p> 43-49. |
Protective |
Hg toxicity |
Dual effects of formylpeptides on the adhesion of endotoxin-primed human neutrophils |
Bellavite P.,Chirumbolo S.,Ferro I. |
Cell. Biochem. |
Inhibitory |
Cell adhesion |
Effects of homeopathic preparations of organic acids and of minerals on the oxidative metabolism of human neutrophils |
Chirumbolo S.,Signorini A.,Bellavite P. |
Br. Hom. J., 1993,<o:p> </o:p> 82: 227-244. |
Inhibitory |
Leucocyteactivation(metabolism) |
Platelets/endothelial cells interactions in presence of acetylsalicylic acid at ultra low dose |
DoutremepuichC.,De Seze O. |
Omeomed 92
(C. |
Inhibitory |
Prostacyclin<o:p> </o:p> release |
Effect of high dilutions of epidermal growth factor (EGF) on in vitro proliferation of keratinocyte and fibroblast cell lines |
Fougeray S.,Moubry K.,Bastide M. |
Br. Hom. J., 1993,<o:p> </o:p> 82: 124-125. |
Inhibitory |
Growth of<o:p> </o:p> keratinocytes |
Effects of different homeopathic potencies of Lachesis on lymphocyte cultures obtained from rabbit blood |
Enbergs H., Arndt G. |
Biol. Tier., 1993, 4. |
Stimulant |
Mitotic andimmunostimulating10-5-10-6) |
The effect of homeopathic potencies of housedust mite on the migration of house-dust sensitive human leukocytes |
Gibson S.L., Gibson R.G. |
Complement. |
Stimulant |
Leucocyte chemotaxis |
The effects of Nux vomica Homaccord and Atropinum comp. on intestinal activity in vitro |
Kanui T.I., Enbergs H. |
Biol. Tier., 1996/1, 43-47. |
Stimulant |
Contraction of intestinal muscles |
Application of flow cytometry to the analysis of the immunosuppressive effect of histamine dilutions on human basophil action: effect ofcimetidine |
Sainte-Laudy J., Belon P. |
Inflamm. Res., |
Inhibitory |
Basophil degranulation |
Effects of Podophillum pellatum compounds in various preparations and dilutions on human neutrophil functions in vitro |
Chirumbolo S.,Conforti A.,et Al. |
Br. Hom. J., 1997;<o:p> </o:p> 86-16. |
Inhibitory |
Release of<o:p> </o:p> superoxides |
In vivo and in vitro studies on the efficiency of potentized and nonpotentized substances |
Harisch G., Dittmann J. |
BT, 1997, 2;<o:p> </o:p> 40-46. |
Difference between potentised and non-potentised substances |
In vivo and in vitro study; basic research |
Experiments with the effects of Ubichinon-Injeel and strong Ubichinon-Injeel on an acellular system |
Harisch G., Dittmann J. |
BM, 1997, 3;<o:p> </o:p> 99-104. |
Different effects of associations of various potencies and individual potencies |
In vitro study;<o:p> </o:p> basic research |
Efficacy of the homeopathic drugs Suis and Arnica comp.-Heel® on lymphocyte and phagocyte activity |
Enbergs H. |
BM, 1998, 1;<o:p> </o:p> 3-11. |
Effect of organotherapeutics and Arnica comp. -Heel® on immune system cells |
In vitro study;<o:p> </o:p> basic research |
Influence of dilutions and potencies of cAMP on different enzymatic systems |
Harisch G., Dittmann J. |
BM, 1998, 2;<o:p> </o:p> 55-62. |
Effects of dilutions and potencies of cAMP on some enzymatic activities |
In vitro study;<o:p> </o:p> basic research |
Studies of the principles of homeopathy; the changeover from in vivo to in vitro experimental research |
Harisch G., Dittmann J. |
BM, 1998, 3;<o:p> </o:p> 98-103. |
Potentised and non-potentised dilutions are equally effective, but have different actions |
Basic research |
Determination of the activity of acid phosphatase with cAMP at various potencies |
Harisch G., Dittmann J. |
BM, 1999, 1; 4-8. |
Different effects on enzymatic activity |
In vitro study; |
Contribution to study of the efficacy of homeopathic potencies of phosphorus |
Gomez J.C. |
BT, 1999, 2; 53-57. |
Effect of different potencies of phosphorus |
Tests on guinea pigs |
Determination of the activity of acid phosphatase in the presence of Ubichinon comp. |
Harisch G., Dittmann J. |
BM, 1999, 4; 188-194. |
Effect of enzymatic activity of homeopathic medicine |
Basic research |
Biochemical efficacy of homeopathic and electronic preparations of D8 potassiumcyanate |
Dittmann J.,Kanapin H.,Harisch G. |
FKM, 1999, 6; 15-18. |
Homeopathic potentisation is more effective than electronic potentisation |
Basic research |
Osteoporosis in vitro in rat tibia derived osteoblasts is promoted by the homeopathic preparation, FMS Calciumfluor |
Palermo C.,Filanti C.,Manduca P. |
Cell Biol Int, 1999,<o:p> </o:p> 23(1): 31-40. |
Stimulant |
Osteogenesis(trial withcompound drug) |
Thin-layer chromatography (TLC) of homeopathic active constituents |
Schmolz M. |
BM, 1999, 5;<o:p> </o:p> 248-250. |
Constituents of Arnica comp.- Heel® ointment: electrophoresis accelerates their skin penetration. |
Basic research |
Effect of homeopathic constituents on enzymatic activity. |
Basic research |
|||
Efficacy of a potentised homeopathic drug in reducing cytotoxic effects produced by arsenic trioxide in mice |
Datta S.,Mallick P.,Khuda Bukhsh A.R. |
Complement Ther |
Protective |
Arsenic trioxide toxicity |
Efficacy of a potentised homeopathic drug in reducing cytotoxic effects produced by arsenic trioxide in mice |
Datta S.,Mallick P.,Khuda Bukhsh A.R. |
Complement
Ther |
Protective |
Arsenic trioxide toxicity |
Non-cytotoxic antiviral action of a homeopathic drug |
Heine H. |
Ärzteitschrift fürNeturheilverfahre, 2000; 41: 542-7. |
Stimulant |
ã interferon<o:p> </o:p> synthesis |
Efficacy of a potentised homeopathic drug in reducing cytotoxic effects produced by arsenic trioxide in mice |
Kundu S.N.,Mitra K.,Khuda Bukhsh A.R. |
Complement
Ther |
Protective |
Arsenic trioxide toxicity |
Stimulatory effect of some plant extracts used in homeopathy on the phagocytosis induced chemiluminescence of polymorphonuclear leukocytes |
Crocnan D.,Greabu M.,Olinescu R. |
Rocz Akad Med |
Stimulant |
Phagocytosis |
Difference between the efficacy of single potencies and chords |
Dittmann J., Harisch G. |
BM, 2000, 1; 18-23. |
Potency chords are more effective than single potencies |
Basic research |
Influence of some homeopathic drugs on the catalytic activity of uricase, acid phosphatase and the cytosol glutathion-S-transferase |
Dittmann J., |
BM, 2000, 3;<o:p> </o:p> 125-131 |
Effect of D8 potencies on three different enzymatic systems |
Basic research |
Influence of some homeopathic drugs on the catalytic activity of cAMP-dependent protein kinases |
Dittmann J.,Kanapin H.,Harisch G. |
BM, 2000, 6;<o:p> </o:p> 289-296. |
Effect of different potencies of 5 substances on enzymatic activity |
Basic research |
Neuroprotection from glutamate toxicity with ultra-low dose glutamate |
Jonas W.,Lin Y.,Zortella F. |
Neuroreport, |
Protective |
Glutamate toxicity |
KEY: BT = Biomedical Therapy
BM = Biologische Medizin
FKM = Forschung Komplementär Medizin
wikified version of the table
I did it to show how it should be coded, instead of fusing html tags. It lacks font tags and cell size tags.
ORIGINAL/TRANSLATED TITLE | AUTHOR(S) | PUBLICATION | ACTIVITY | STUDY |
---|---|---|---|---|
Inhibition of lymphoblast transformation test (LTT) in phytohaemagglutinin Phytolacca americana in homeopathic dilution | Colas H, Aubin M., Picard P.,Lebecq J.C. |
Ann. Homéopat. 1975 6: 1-11. | Inhibitory | Lymphoblast transformation |